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Abstract
Sample preparation as an essential step in mass spectrometry-based analysis, plays a
critical role in proteomics studies. Magnetic nanoparticles (MNPs) have been widely used in
protein and peptide sample preparation due to their magnetic properties, biocompatibility, easy
synthesis and surface functionalization. MNPs loaded with analyte or analyte modification
reagent can be easily separated from the reaction medium by an externally applied magnetic
field. The small size of MNPs provides high analyte loading and extraction capacity.
Additionally, MNP can be decorated with different functional groups to achieve selective
modification or extraction of analyte. In this study we have utilized silica coated iron oxide
magnetic nanoparticles (Fe3O4 @SiO2 MNPs) for protein and peptide sample preparation.
Fluorescence-based methods were utilized for quantitative and qualitative
characterization of N-hydrosucccinimidyl (NHS) ester groups on the surface of Fe3O4 @SiO2
MNPs. Fluorophore Dansylcadaverine was conjugated to NHS ester functional groups.
Fluorometric measurement of cleaved dansylcadaveine was employed to determine the number
of NHS ester groups per MNPs that was found to be 2.6 × 102 and 3.4 × 103for 20 nm and 100
nm Fe3O4 @SiO2 MNP respectively. The efficiency of labeling native bovine serum albumin
(BSA) by NHS ester coated Fe3O4@SiO2 MNPs was also explored in terms of maximizing the
number of MNPs conjugated per BSA molecule or maximizing the number of BSA molecules
conjugated per each MNP.
Lysine residues of apolipoprotein B-100 (apoB-100) on the surface of intact human low
density lipoprotein (LDL) were labeled by NHS ester modified Fe3O4 @SiO2 MNPs in aqueous
solvents at room temperature. The MNP labeledapoB-100 was treated by SDS to remove lipids

x

and then digested using trypsin. Tryptic peptides were eluted from MNPs by cleaving disulfide
linkage between labeled peptides and MNPs. LC-MS/MS analysis found 28 peptides containing
labeled lysine residues. These lysine residues should be on the solvent exposed surface of LDL
since the large size of MNPs prevents contact of the labeling reagent to those lysines embedded
inside the structure of LDL.
TCEP- immobilized Fe3O4@SiO2MNPs were fabricated and utilized for reduction of
disulfide bonds in bovine pancreas insulin and two different cyclic peptides. Disulfide bonds
were efficiently cleaved at room temperature in both organic and aqueous solvents confirmed by
LC-MS/MS analysis of reduced/alkylated protein and peptides. Disulfide reduction and
alkylation reactions was performed in one step and the reducing agent was simply separated from
peptide and protein solution by magnetic separation.

Keywords: Silica coated iron oxide magnetic nanoparticles (Fe3O4 @SiO2 MNPs),Nhydrosucccinimidyl (NHS) ester, fluorometric quantification, protein labeling efficiency,
apolipoprotein B-100 (apoB-100),low density lipoprotein (LDL), surface exposed lysines,
disulfide bond, TCEP- immobilized Fe3O4@SiO2 MNPs, LC-MS/MS.
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Chapter1
Introduction
Proteomics, as a large scale comprehensive analysis tool forproteins, allows us to zoom
in on biological processes at molecular level. Proteomics studies help researchers to explore the
connections between genes, proteins and diseases and therefore plays a crucial role in disease
recognition, drug development and molecular medicine. The application of nanomaterials in
proteomics is expected to have significant impact on the future direction of research in this field.
Magnetic nanoparticles (MNPs), and particularly magnetite (Fe3O4), as well established
nanomaterials, have recently attracted a great deal of interest due to the important possibilities
they can offer in biomedical studies. Synthetic magnetic nanoparticles have controllable sizes
ranging from a few to several hundreds of nanometers – smaller than the size of a cell (10-100
µm) but comparable to the dimension of cell components such as proteins (5-50 nm). The similar
size of nanoparticles and proteins makes them relatively easy to get close to each other and
integrate. Magnetic nanoparticles can be easily surface-functionalized with a variety of ligands
which can selectively bind to or interact with specific sites of proteins. Due to their ability to
respond to magnetic fields, magnetic nanoparticles coated with various peptide reactive groups
can be effectively used for protein isolation, purification and enrichment.
In this study we have utilized silica coated magnetic iron oxide nanoparticles
(Fe3O4@SiO2 MNPs) with well tailored surface functionalities for protein sample preparation
and analysis. This thesis is divided into five parts. The introductory Chapter provides
information about the key concepts that are related to the studies presented in this dissertation.
The second Chapter describes the quantification of active functional groups on the surface of
1

Fe3O4@SiO2MNPs using different methods. The third Chapter evaluates the use of Fe3O4 @SiO2
MNPs in separation of lipid bound proteins such as ApoB-100 as well as application of these
nanoparticles in labeling surface exposed lysine groups of ApoB-100 in native low density
lipoprotein (LDL). The fourth Chapter is about the application of TCEP-immobilized
Fe3O4@SiO2 MNPs in reduction and alkylation of disulfide bonds in both cyclic peptides and
proteins. The last Chapter summarizes the performed work and also provides suggestions for
future studies.

1.1 Magnetic iron oxide nanoparticles-applications, synthesis, functionalization and
quantification of surface ligands
Nanoparticles are submicron entities (with the diameter ranging from 1-100 nm)
composed of organic or inorganic materials.1 Magnetic nanoparticles (MNPs), as one of the most
well-established nanomaterials, possess unique magnetic properties such as superparamagnetism,
high coercivity, low Curie temperature and high magnetic susceptibility.1 MNPs have attracted a
lot of attention due to their broad range of applications including magnetic fluids, data storage
and catalysis.1-6 In recent years MNPs have also been extensively used for various biological,
diagnostic and therapeutic applications such as separation and detection of cells and cell
ompartments (protein, nucleic acids, enzymes), magnetic resonance imaging, magnetic fluid
hyperthermia and targeted drug delivery.1, 7-10
Magnetite (Fe3O4) and maghemite (ϒ-Fe2O3) are two major forms of magnetic
nanoparticles used in biomedical applications. The applications of iron oxide MNPs are highly
influenced by their shape, size and size distribution, surface and magnetism.11 Therefore, having
good control over the properties of MNPs during the synthesis and functionalization is crucial for
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their successful application. The most common methods to synthesize MNPs are: thermal
decomposition, hydrothermal synthesis, co-precipitation, microemulsion and sonochemical
synthesis.12 Thermal decomposition and hydrothermal methods were employed to synthesize
magnetic Fe3O4nanoparticles which have been used in our studies.
Thermal decomposition methods have been employed for fabrication of monodisperse
size controlled magnetic iron oxide nanoparticles. Thermal decomposition of organoiron
precursors such as iron penta carbonyl (Fe(CO)5) andiron (III) acetylacetonate(Fe(acac)3)in
presence of surfactant generates nanoparticles with controlled size (ranging from 4 to 20nm).13-15
More environmental friendly alternatives to the aforementioned precursors are iron chloride and
other iron oxides which have been widely used in recent years.16-19 The magnetic iron oxide
nanoparticles generated by thermal decomposition methods are well dispersed in organic
solvents.
The hydrothermal method is a simple and environmental friendly procedure for the
synthesis of magnetic iron oxide nanoparticles that does not require organic solvents. The
reactions are performed in aqueous solutions at high pressure (>2000 psi) and temperature20
(200-300 °C). The nucleation and growth processes of the nanoparticles are influenced by
several factors including reaction time, temperature and solvent composition21. To generate
nanoparticles with well defined shape and narrow size distribution, polyols (such asethylene
glycol, diethylene glycol, polyethylene glycol) have been used as solvents.22,23 Polyols also act as
reducing and stabilizing agents that prevent the aggregation of nanoparticles.24 The nanoparticles
made by this method are coated with hydrophilic ligands, which make them well dispersible in
polar solvents.
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Surface coating of magnetic nanoparticles with inert materials such as silica increases the
chemical stability and biocompatibility of magnetic nanoparticles.25 Silica coating also enhances
the colloidal stability of the magnetic nanoparticles due to the electrostatic repulsion induced by
silica shell. Moreover, the silica layer serves as a platform for surface functionalization of
magnetic nanoparticles.26 In our studies, we followed the two most common approaches for
silica coating of magnetic nanoparticles: the Stöber method and inverse microemulsions.
Stober method relies on hydrolysis-condensation reaction of tetraethyl orthosilicate
(TEOS) as the silicon dioxide precursor.27 The hydrolysis and polycondensation of TEOS in
basic solution leads to formation of an amorphous silica shell. The thickness of the silica layer
can be controlled by changing the concentration of TEOS, the type of solvent, the amount of
waterand the concentration of base.28-31
Water in oil microemulsions (W/O, also called inverse microemulsions) are well known
methods for synthesis of silica coated magnetic nanoparticles with narrow size distribution.32 In
these methods, water nanodreoplets aredispersed in the organic (oil) phase and stabilized by a
nonionic surfactant. The water nanopoolsin the internal core of the micelles serve as
nanoreactors in which the silica shell forms around the iron oxide cores via hydrolysiscondensation reaction of TEOS. The size of these water nanopools and consequently the size of
the silica coated nanoparticles can be changed by varying the ratio between the organic and
aqueous phase, the concentration of reactants, the reaction temperature and the type of
surfactant.33
Functionalization of nanoparticles is a critical step in various bio-applications. Different
functional groups such as carboxylic acid,34,35 thiol36,37 and amine38 are immobilized on the
surface of the nanoparticles before further conjugation to the biomolecules. The application of
4

the nanoparticles is usually defined by the ligands present on the their surface. Accurate
measurement of the active functional groups is very important to evaluate the efficiency of
further chemical conjugation reactions.
Despite dramatic improvements in the synthesis of biocompatible nanoparticles, less
attention has been paid to quantification of intermediate functional groups and exposed ligands
on the surface of NPs. Common spectroscopic techniques such as IR and XPS showed low
sensitivity towards the quantification of surface functional groups.39,40 Fluorometric41,42and
colorimetric techniques,43high resolution mass spectrometry,44 combustion analysis45 and ATRFTIR39,40have also been used to quantify the surface functional groups. Each of these
aforementioned methods has its own disadvantages that prevent accurate quantitative
measurement of surface functional groups.
Chemical labeling approaches, which relyon covalent attachment of a
chromophore/flurophore to the surface functional groups, have also been employed for surface
characterization of nanomaterials. These methods are simple, sensitive and nondestructive.
However, the direct quantification ofchromophore/flurophore attached to the surface of
nanoparticles could be problematic due to the possible fluorescence quenching effect of some
type of nanoparticles. This problem can be solved by inducing a specific cleavageof conjugated
fluorophore from NPs prior to measurements.46 Dansyl derivatives have been widely used as
fluorophores in covalent labeling and quantification of aldehyde, ketone and carboxylic acid
functional groups on the surface of nanomaterials.47,48, 49

5

1.2 Cardiovascular diseases (CVD)
Cardiovascular disease (CVD) is a collective term to describe disorders that affect the
function of the heart and the blood vessel system (arteries, veins and capillaries) including
coronary heart diseases, cerebrovascular diseases (stroke), peripheral arterial diseases, rheumatic
heart disease, congenital heart disease, deep vein thrombosis and pulmonary embolism. The two
most important forms of CVD are coronary heart disease and stroke. Coronary heart disease
refers to a blockage of the arteries that supply oxygen to the heart muscle, which results in a
heart attack. Stroke occurs when the blood flow to the brain is blocked or interrupted as a result
of either blockage(ischaemic stroke) or the rupture of a blood vessel50(hemorrhagic stroke).
Cardiovascular disease is the world's leading cause of death accounting for one third of
all deaths globally. Figure 1.1 shows the trends in CVD mortality as well as the expected shift
from infectious to chronic disease over the next few decades.51According to World Health
Organization (WHO) estimates, 17 million people die each year from CVD. Of these, an
estimated 7.2 million were attributed to coronary heart disease and 5.7 million were due to
stroke.52 The annual CVD deaths are expected to rise to 24 million by 2030.52 The epidemic of
CVD is also shifting from devolved to developing nations andnearly80 percent of the CVD
deaths occur in low and middle income countries. The largest percentage increase in CVD deaths
is expected to occur in the Eastern Mediterranean Region.52
Several risk factors are associated with CVD, which can be classified as modifiable and
non-modifiable risk factors. Non-modifiable risk factors include gender, ethnicity, age and
family history. Modifiable risk factors, which can be prevented, treated and controlled include
tobacco smoking, insufficient physical activity, high blood pressure, high blood cholesterol,
obesity and unhealthy diets.52,53 It is an undeniable fact that diet has a crucial role in
6

development and prevention of CVD. A high level of blood cholesterol has been known as a
major risk factor for cardiovascular disease.52,53 Although studies show a declining trendin total
average blood cholesterol level for adult Americans (Figure 1.2), elevated cholesterol should still
be considered as a serious health threat.

Figure 1.1:Global mortality projection by cause.51
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Figure 1.2: Age adjusted trends in mean plasma LDL-cholestrol for total population and by gender.54

1.3 Low density lipoproteins (LDL)
Lipoproteins are micelle-like particles consisting of lipids and proteins held together by
non-covalent interactions that enable lipid transport in the aqueous environment of body
fluids.55,56.The main groups of lipoproteins are classified as chylomicrons, very low density
lipoprotein, low density lipoproteins(LDL), intermediate density lipoproteins (IDL) and high
density lipoproteins (HDL). LDL, as the main cholesterol carrier in the physiological system, is
synthesized in the liver. LDL is often called "bad" cholesterol since an elevated level of LDL is
associated with cardiovascular diseases.57, 58Higher levels of HDL or "good" cholesterol reduce
the risk of CVD.59,60
LDL particles (Figure 1.3), with an average molecular weight of 3 million Daltons,
consist of a non-polar core including cholestryl ester and triglycerides. The hydrophobic core of
LDL is surrounded by an outer monolayer consists of phospholipids and free cholesterol. The
8

only protein component of LDL is apolipoprotein B-10061 (apoB-100). Cholesterol, which is
vital for proper function of cells, has several roles including stabilization of cell membranes.
When needed, cholesterol is acquired by cells via receptor mediated endocytosis of LDL
particles.62 After binding to the LDL receptor on the cell surface, the LDL-bound protein is then
internalized by endocytosis forming a clatherin-coated pit which will pinch off to form a
clatherin vesicle. The acidic pH of the endosome leads to protonation of the LDL receptor and
finally freeing of the bound LDL particles. The enzymatic digestion of LDL particles in
lysozomes breaks down the ApoB-100 to amino acids and release cholesterol. The LDL
receptors are recycled back to the cell membrane via transport vesicles.62

Figure 1.3: Schematic representation of an LDL particles.

9

1.4 Apolipoprotein B-100 (ApoB-100)
ApoB-100, the exclusive protein constituent of LDL, is one of the largest monomeric
protein known with the molecular weight of 550 kDa.63-65Apo B-100, as a ligand for receptormediated endocytosis of LDL,66is produced in the liver and contains 4563 amino acids. It has
been difficult to determine the structure of ApoB-100 due to the very large size of the molecule,
which hinders the production of good quality X-ray diffraction crystals.ApoB-100 is insoluble in
the aqueous environment once it is delipidated, which makes the structural analysis even more
difficult.67
Despite extensive studies on APOB-100 structure over the last two decades,64, 68 the
structure of ApoB-100 is still not well characterized. The results from calorimetric and x-ray
diffraction studies as well as cryo-electron microscopy indicated that ApoB-100 wraps around
the outer surface of LDL particles.69-71 Circular dichroism (CD) and helical wheel analysis
showed the presence of 25% α helical content.72These methods also provided some information
aboutthe role of disulfide linkage in the conformation ofApoB-10073 as well as the lipid
associating motifs of ApoB-100.74The presence of β sheet structure in ApoB-100was also
confirmed by infrared spectroscopy and CD studies.1D NMR75 and 2D NMR76 were used to
detect different populations of solvent exposed lysine groups of ApoB-100.
Molecular modeling techniques has shed some light on the ApoB structure using the
ApoB sequence homology to lipovitellin, which is a protein found in egg yolk.77 It was found
that the N-terminal residues of ApoB and lipovitellin are very similar showing, up to
20.5%sequence match78. Further analysis using the homology search program (BLAST) showed
that the sequence similarity between ApoB and lipovitellin extends beyond the N-terminal amino
acids to include the first 1000 amino acid residues in ApoB-100.79
10

The oxidative modification of ApoB-100 in the presence of radicals has been studied in our
lab.80, 81 The oxidation was carried out prior to the delipidation process, and the modified
peptides were analyzed by liquid chromatography tandem-mass spectrometry (LC-MS/MS).
Covalent labeling of the solvent exposed amino acid residues is a challenging task due to the
ability of small labeling reagents to cross the lipid layer and modify the internal amino acid
residues embedded inside the structure of ApoB-100.
ApoB-100 contains both hydrophobic regions that bind to lipids and hydrophilic regions
that interact with the aqueous phase. ApoB-100 has a pentapartite structure, NH2 - βα1- β1 - α2 β2- α3 -COOH, consisting of three α-helices and two β-strands in between the α-helices.62βdomains of ApoB-100arerigid and irreversibly associated with the neutral lipid core of LDL
particles, providing stability to the LDL particles, while α-helices give more elasticity to the
ApoB molecule.62 The amphiphilic characteristic of ApoB is crucial in preserving the integrity of
LDL particles during lipid transport in the blood.

1.5 Mapping protein structure using Amino acid-specific covalent labeling
Combining mass spectrometric analysis with covalent modification of specific amino
acids residues in proteins is a very useful approach to obtain important information about the
sequence, structure and surface topology of proteins,77specially in those systems which are
difficult to study by other methods. Electrospray ionization(ESI) and matrix-assisted laser
desorption ionization (MALDI) followed by tandem mass spectrometric analysis have been
employed to identify the sites of covalent modifications, providing important site-specific
structural information about proteins.78The covalent labeling methods rely on differential
reactivity of amino acid side chain towards labeling reagents. The reactivity of amino acids in
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proteins depends on several factors including accessibility of the side chain to the reagent, the
inherent reactivity of the label and the reactivity of the amino acid side chain.78
Covalent labeling is usually performed using either non-specific or specific labels.
Oxidative footprinting methods using radicals are an example of nonspecific covalent labeling.7981

On the other hand, side chains of many amino acids have been selectively modified using

covalent labels that target specific functionalities such as sulfuhydryls (cysteine), amines (lysine)
and carboxylic acids82-85 (aspartic acid and glutamic acid).
Iodoacetic acid and iodoacetamide have been extensively used for probing cysteine
groups in proteins. Maithal et.al used these reagents to determine the differential reactivity of
cysteine residues in Plasmodium falciparumtriose-phosphate isomerase.85Whitehurst et al.
studied the accessibility of cysteine residues for covalent modification with iodoacetamide in the
Sindbis virus E1 and E2 glycoproteins by incubation of the native virus particles with the
labeling reagent.86 Covalent modification of lysine groups with amine reactive reagents such as
N-hydroxysuccinimidyl (NHS) esters,82,87 sulfo-NHS esters,88 isothiocyanates,89 and
isocyanates90 has been of particular interest in protein structural studies due to the fact that lysine
residues are more abundant compared to cysteine residues.82,91 Solvent exposed lysine residues
of ApoB-100 were modified by 13C methyl groups followed by NMR characterization.92Patil et
al. fabricated NHS ester modified Fe3O4@SiO2 magnetic nanoparticles with a cleavable disulfide
bond linker to label primary amine groups on the solvent accessible surface of bovine serum
albumin82 (BSA).

1.6 LC-MS/MS based proteomics
Proteomics is the large scale structural and functional analysis of protein molecules,
which are vital components of living organisms. Proteomics is not only used for protein
12

sequencing but also provides detailed information about the protein abundances, protein-protein
interactions and post translational modifications.79, 93-95 Mass spectrometry, as one of the most
sensitive analytical techniques, has made an enormous contribution in development of
proteomics to its current capabilities. Initially, mass spectrometry was used in combination with
2-dimensional gel electrophoresis (2DE)for individual protein sequencing and identification of
gel bands.96 Analysis of complex protein and peptide mixtures became possible after combining
the liquid chromatography separation techniques with mass spectrometry.97

In mass spectrometric analysis of proteins, two soft ionization techniques are commonly
used. In MALDI technique,98 the analyte is mixed with an organic matrix. The energy of the
laser beam is then transferred to the sample though the matrix, which causes the simultaneous
desorption and ionization of the analyte. In ESI method, a high voltage is applied to the analyte
solution which results in formation of charged droplets that in turn rapidly evaporate and become
smaller as they are dragged along the ion passage by potential and pressure gradients. As the
droplets become smaller, they repel each other because of the increased surface charge density
and burst into smaller droplets. Once the solvent is completely removed, the analyte ions enter
the mass spectrometer and can be easily analyzed.

In our instrumental design, peptide ions entered a hybrid quadrupole time of flight mass
spectrometer (Agilent 6520 Q-TOF mass spectrometer coupled with HPLC) after desolvation. 99,100
The quadruple guides ions through the analyzer region in MS mode and also serves as a mass
selection tool in MS/MS mode. A time-of-flight (TOF) analyzer, which is placed orthogonally to
the ion beam exiting the quadrupole, resolves different mass ions in both MS and MS/MS
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modes. In MS/MS analysis, the fragmentation takes place in the collision cell, which is located
between the quadrupole and the TOF analyzer. Nitrogen was used as collision gas. The sample
separation using liquid chromatography prior to mass detection, increases the sensitivity of the
mass spectrometric analysis of complex protein and peptides samples.

1.7 Database Search
The data acquired in a common LC-MS/MS analysis includes a complex collection of
precursor ions intensities and the associated MS/MS spectra from which we can obtain valuable
information by performing a database search. Different search algorithms are available to
identify the peptides in complex biological mixtures. In our studies, the full length cDNA
sequences for ApoB-100 (Swiss-Prot accession # P04114) and bovine insulin (GenBank
accession #550058A) were processed by the PEAKS database search program. After adding the
sequence to a database, the software performs in-silico (performed via computer simulation)
cleavage of the polypeptide sequence to create theoretical precursor ions. The fragmentation of
these precursor ions generates corresponding product ions.

The PEAKS software matches the theoretical b (charge is retained on the N-terminus)
and y (charge is retained on the C terminus) ions with the experimental tandem mass spectra and
generates a score called the linear discriminative function (LDF) to evaluate the quality of match.
The LDF score not only finds the most likely correct peptides in each spectrum of the tandem
mass dataset, but also efficiently separates true and false identifications.101, 102 The LDF score is
then converted to a P-value to facilitate the data interpretation. For a given LDF score, its
equivalent P-value is the probability that a false identification has a score>LDF. The smaller the
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P-value the less likely the peptide-spectrum match is a random match101. The p value is then
converted to -10*log10(P-value), which is a more human friendly representation. In this case, a
better match has a higher -10logP value. AP-value of 1% is equal to -logP of 20.102

1.8 Disulfide bonds in proteins
Disulfide bonds are covalent linkages between cysteine pairs, which are formed due to
the oxidation of cysteines.103Disulfide bonds exist in proteins of both prokaryotic and eukaryotic
cells. Disulfide bond containing proteins are usually found in the endoplasmic reticulum of
prokaryotic cells or the preplasmic space of bacteria.103 Both intermolecular (between different
polypeptide chains) and intramolecular (within the polypeptide chain) disulfide bonds play
crucial role in folding of proteins into their native, three dimensional and active structures.103
Insulin, an example of disulfide bond containing proteins, is an essential hormone produced by
the pancreas beta cells and plays a crucial role in metabolism of carbohydrates and fats. Mature
insulin, with the molecular weight of 5733 Da, contains 51 amino acids in two polypeptide
chains. The A chain has21 amino acids (A1-A21), and the B chain has30 amino acids (B1-B30).
These chains are connected via two interchain disulfide bonds (A7-B7 and A19-B20). There is
also an intrachain disulfide bond (A6-A11) within the A chain of insulin.102The first precursor of
insulin (preporinsulin) contains an amino terminal signal sequence which is cleaved during the
process of transferring to the endoplasmic reticulum. Cleavage of the signaling sequence
generates the second insulin precursor called proinsulin, which is finally converted to the mature
insulin by removing the internal connecting polypeptide105 (C chain).
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1.9 Reduction and alkylation of proteins
Generating protein fragments via proteolytic digestion is a crucial step in structural
analysis of proteins by mass spectrometry. The efficiency of proteolytic digestion depends on the
accessibility of the enzymes, such as trypsin, to their potential cleavage sites, which could be
hindered if the protein is folded.106Disulfide bond reduction unfolds protein and improves the
efficiency of the digestion process by making the cleavage sites accessible to the enzyme. This
ultimately increases the protein sequence coverage and improves the protein identification by
mass spectrometry.107, 108
Various reducing agents such as dithiothreitol (DTT), β-mercaptoethanol (BME), and
tris-(2-carboxyethyl) phosphine hydrochloride(TCEP) have been used for the reduction of
disulfide bonds in peptides and proteins.108The application of BME and DTT is limited by
several factors including low stability, pH sensitivity and incompatibility with sulfhydryl
modifying reagents. TCEP has been extensively employed for reduction of disulfide bonds in
peptides and proteins due to its advantages of being odorless, active over a wide range of pH,
more resistant to air oxidation and more water soluble.109-114 Additionally, TCEP does not
interfere with most of the thiol labeling reactions, which eliminates the need of its removal
before the modification of free thiol groups.109, 115, 116 The reduction of disulfide bonds using
TCEP is typically done by simply mixing the reducing reagent with proteins over a specific time
(ranging from 30 min - 24 hr) at a specific temperature109 ( ranging from room temperature to 60°
C).
The free thiol groups generated by disulfide bond cleavage are highly reactive and could
be oxidized easily to reform disulfide bonds. Reformation of disulfide bonds can often be
avoided by blocking the free thiol groups via alkylation reactions. Vinylpyridine, iodoacetamide,
16

iodoacetic acid and iodoethanol are common alkylating reagents among which iodoacetamide
has been extensively used since it is odorless and more stable.116,117 The alkylation reaction using
iodoacetamideis usually carried out in the dark at 37°C for a specific time ranging from 30min to
1hr.118
TCEP does not contain a thiol, which makes it uncreative towards most of the thiol
labeling reagents. However, TCEP shows some degree of reactivity towards certain chemicals
thatare commonly used for labeling proteins and peptides.118,119 In this case, TCEP should be
removed before further modification of the reduced proteins. Immobilization of TCEP on solid
supports such as hydrophilic PEG resins120 and monolithic silica109 chips eliminates the need to
perform time consuming and laborious methods such as dialysis and gel filtration, which are
commonly used for separation of reducing agents from protein solution.
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Chapter 2
Protein surface labeling reactivity of N-hydroxysuccinimide ester group
conjugated to Fe3O4@SiO2 magnetic nanoparticles
This Chapter presents a collaborative work between Parisa Pirani,Ujwal S. Patil, Tushar
Dattu Apsunde,Mark L. Trudell,Yang Cai, and Matthew A. Tarr. Howerevre, the experiments
are predominantely performed by Parisa Pirani.

2.1 Introduction
Among different types of nanomaterials, iron oxide magnetic nanoparticles have attracted
great deal of interest mainly due to their superparamagnetization properties1,2 as well as simple
preparation. Separation of ligands that are covalently or non-covalently attached to the iron oxide
nanoparticles can be easily done using an external magnet, and the nanoparticle-ligand
conjugates are easily re-dispersible in solution by removing the magnetic field. The synthesis of
magnetic iron oxide nanoparticles is quite simple, and the stability and aqueous compatibility3 of
these nanoparticles could be significantly improved be coating them with silica, polyethylene
glycol, dextran and other coating agents. The surface of MNPs could be easily modified with
different functional groups, such as amine, thiol and carboxylic acid before further conjugation
of other ligands.4 The application of nanomaterials such as MNPs is usually defined by the
ligands present on their surface.
Accurate quantification of reactive functional groups (amine, thiol, carboxyl, etc.) on the surface
of nanomaterials is essential for further conjugation of biomolecules to the surface. Although
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numerous efforts have been made on preparation and surface functionalization of biocompatible
nanoparticles, less research has been carried out on quantification of intermediate functional
groups and exposed ligands on the nanomaterials’ surface. A common approach to quantify
ligands on solid surfaces involves covalent or non-covalent conjugation of a
chromophore/flurophore to the surface functional groups. Quantification of the conjugated
chromrophore/fluophore determines the equivalent amount of ligands on the solid surfaces.5
Amine groups on solid surfaces have been quantified via covalent interaction with a
chromophore/flurophore. Few examples include fluroscamine assay6,7,8 fluorescent Fmoc-CL
assay,9,10NHS-fluorescein assay,11 4-nitrobenzaldehyde detection using UV-Vis
spectroscopy12,13,14 and bromophenol blue assay.14 Amine groups on a glass slide were quantified
via covalent conjugation to a carboxyl modified fluorescent dye (4,4-difluoro-5,7-dimethyl-4bora-3a,4a-diaza-s-indacene-3-propionic acid) followed by fluorometric quantification of the
fluorophore conjugated amine groups.15 To quantify thiol groups on solid surfaces, Ellman's
reagent was covalently conjugated to the free thiol groups followed by measuring the yellow
colored fluorophore conjugated product.16 Aldehyde groups on a glass slide were quantified by
covalent conjugation of this functional group to a hydrazine modified fluorescent dye (4,4difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid, hydrazide), followed by
fluorometric measurement.15 Cleave-analyze quantification approach has been employed to
avoid any interference from solid surfaces. In this method, fluorophores/chromophores
covalently conjugated to the surface are detached prior to the fluorometric measurement.17
Quantification of amine groups on solid surfaces has also been performed via non-covalent
attachment of chromophores/fluorophores such as orange II dye18 or coomassie brilliant blue
(Bradford assay)19 to amine groups.
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Time of flight-secondary ion mass spectrometry (ToF-SIMS),20 carbon-hydrogennitrogen combustion analysis,21 and X-ray photoelectron spectroscopy (XPS) were used to
quantify primary amine groups.18,22 Thiol groups on the surface of gold nanoparticles were
quantified by using inductively coupled plasma-mass spectrometry (ICP-MS). 23,24 Yan et al
recently quantified dopamine anchoring group on the surface of MNPs by using laser desorption
ionization mass spectrometry (LDI-MS).25 These elemental analysis approaches (ToF-SIMS,
XPS, ICP-MS, and LDI-MS) are more suitable for smaller nanoparticles such as gold
nanoparticles with less atoms.18 Indirect quantification of ligands on solid surfaces has been also
performed by measurement of the side-products in the reactions that further modify the ligands.
For example, the heterobifucntional crosslinkers N-(succinimidyl 3-(2-pyridyldithio) propionate
(SPDP) and succinimidyl 6-[3´-(2-pyridyldithio)-propionamido] hexanoate (LC-SPDP) react
with primary amine groups and quantitatively yield pyridine-2-thione. The amount of amine
groups immobilized on solid surfaces has been determined by Spectrophotometric measurement
of pyridine-2-thione.26,18,27 Thiol groups on chitosan MNPs were quantified via an indirect iodine
titration in which thiol groups were oxidized by iodine, and the remaining iodine in solution was
determined by the brilliant blue colour resulting from the starch-iodine complexion.16 To
calculate the amount of thiol groups, the unconsumed iodine was subtracted from the initial
amount of iodine added. These indirect measurement methods are ligand specific and highly
dependent on the ligand modification reaction. Hydroxyl, carboxylic acid and aldehyde/ketone
groups on solid surfaces were quantified via depletion approach that measures the difference
between initial and final amount of flurophore after covalent conjugation to the surface. 28,29,30
Moreover, Fourier transform-infrared (FTIR) absorbance spectroscopy was used for quantitative
monitoring of ester carbonyl and aldehyde carbonyl groups in benzimidazole synthesis reaction
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on solid phase,31and relative quantification of carbonyl containing ligands on the surface of gold
nanoparticles.32
NHS ester modified Fe3O4@SiO2 MNPs with cleavable disulfide bond linker have been
recently employed in our lab to label primary amine groups on the solvent accessible surface of
proteins.33 The reaction between NHS ester moiety and primary amine group was performed
under conditions that the native structure of protein was preserved. To confirm the presence of
NHS ester moiety on the surface of Fe3O4@SiO2 MNPs, we developed a sensitive fluorescence
microscopic approach based on covalent attachment of fluorophore dansylcadaverine to MNPs.
The amount of dansylcadaverine34 conjugated to Fe3O4@SiO2 MNPs was determined through a
cleave-analyze approach. Quantification of released/modified fluorophore via fluorometric
HPLC analyses, determined the equivalent amount of NHS ester/thiol groups on MNPs surface.
Accurate quantification of NHS ester groups on Fe3O4@SiO2 MNPs surface provided the basis
for investigations on the reactivity of the magnetic nanoparticle reagent in labelling native
proteins.

2.2 Experimental procedures

2.2. 1 Materials
All chemicals were of reagent grade, obtained from commercial sources and used as
received without further purification unless specified otherwise. Ferric (III) chloride
hexahydrate, (99%), iron (III)oxide hydrated FeO(OH), oleic acid, dimethyl sulfoxide (DMSO,
anhydrous), (3-mercaptopropyl)trimethoxysilane (MPTMS, 99%), tetraethylorthosilicate (TEOS,
99%), Igepal CO-520, cyclohexane, dansylcadaverine, (≥97%) and bovine serum albumin (BSA)
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were purchased from Sigma-Aldrich (St. Louis, MO). Anhydrous trisodiumcitrate (99%), 1octadecene, and anhydrous sodium acetate (99%) were purchased from Alfa Aesar (Ward Hill,
MA). Sodium citrate dihydrate was purchased from J. T. Baker Chemicals (Center Valley, PA).
Ammonium hydroxide, hydrochloric acid and Phosphate buffered saline (PBS)were purchased
from EMD Millipore (Billerica, MA). Ethylene glycol was purchased from VWR (Radnor, PA ).
(3,3´-Dithiobis[sulfosuccinimidylpropionate]) (DTSSP) and a micro bicinchoninic acid (BCA)
protein assay kit were purchased from Pierce (Rockford, IL). (N-succinimidyl 3-[2-pyridyldithio]
propionate (SPDP, 99+%) was purchased from Molecular Biosciences (Boulder,CO). Tris(2carboxyethyl)phosphine hydrochloride (TCEP-HCl) was purchased from Amresco (Solon, OH).
Ethanol was purchased from Pharmco-AAPER (Brookefield,CT). Nanopure water (18.2 MΩ,
Millipore Co. Billerica, MA) was used for all experiments.

2.2. 2 Synthesis of silica coated iron oxide nanoparticles (Fe3O4@SiO2 NPs, diameter100
nm)
The Fe3O4 @SiO2 NPs (100 nm diameter) were prepared according to a previously
reported method1. Initially, FeCl36H2O (0.67 g) was dissolved in ethylene glycol (12.5 mL)
under constant magnetic stirring for 30 min in a Teflon® coated 30 mL autoclave container (Parr
Instrument Company, St. Moline, IL). To the FeCl3 solution, anhydrous sodium acetate (1.35 g)
and anhydrous trisodium citrate (0.5 g) were added, and the mixture was stirred vigorously for
120 min. The autoclave container was sealed tightly and heated at 200°C for 6 hr. The black
suspension of Fe3O4 NPs was washed several times with ethanol and water using magnetic
separation and air dried at room temperature (Scheme2.1). The Fe3O4 NPs (0.1g) were put into
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1M HCl (15 mL) and stirred on a vortex mixer for 10 min. The magnetic NPs were isolated by a
magnet, washed with water and re-suspended in aqueous sodium citrate (10wt%) followed by
stirring for 30 min. The citrate complexed Fe3O4 NPs were magnetically separated and
resuspended in a mixture of ethanol (80 mL), water (20 mL) and ammonia solution (2 mL, 28
wt%) under ultrasonication for 15 min. TEOS (99%, 1 mL) was added dropwise to the above
mixture followed by mechanical stirring (400 rpm) for 12 hr at room temperature. The prepared
silica coated magnetite (Fe3O4@SiO2) nanoparticles were magnetically separated and washed
repeatedly with ethanol. Empty silica shells were carefully removed during the process. The
Fe3O4@SiO2 NPs (100 nm diameter)were immersed in freshly prepared HCl (4N) for 10 min to
remove bare iron oxide NPs. The separated particles were then washed with nanopure water and
air dried at room temperature.

Schematic 2.1: Synthesis of Fe3O4 MNPs (80 nm in diameter) by hydrothermal method.

2.2. 3 Synthesis of silica coated iron oxide nanoparticles (Fe3O4@SiO2 NPs, 20 nm
diameter)
The iron oxide core was prepared by previously reported method. 2 To prepare iron oxide
core, FeO(OH) (0.178 g), oleic acid (2.26 g) and 1-octadecene (5.00 g) were mixed in a three
neck flask and heated at 320°C for 60 minutes. The resulting brown colored solution was washed
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with ethanol using magnetic separation and re-suspended in 25 mL toluene to prepare 10 mg/mL
solution (Scheme2.2).
The iron oxide core (400 µL of 10 mg/mL) was re-suspended in cyclohexane (4 mL) and
Igepal-CO-520 (0.247 g) and sonicated for 15 minutes. TEOS (25 µL) was added and sonicated
further for 10 minutes followed by addition of aqueous ammonium hydroxide (50 µL, 30 wt%)
with additional sonication for 15 minutes. This solution was stirred at room temperature for 24
hours. The Fe3O4@SiO2 NPs(20 nm diameter) were washed with water and ethanol three times
followed by treatment with 4N hydrochloric acid. The resulting silica coated magnetic
nanoparticles were washed several times with nanopure water and air dried at room temperature
prior to TEM observation.

Schematic 2.2: Preparation of Fe3O4@SiO2 MNPs (~20 nm in diameter, with a iron oxide core of (~10 nm
in diameter) by thermal decomposition plus reverse microemulsion method.
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2.2. 4 Surface functionalization of Fe3O4@SiO2 NPs (100 nm and 20 nm in diameter) with
NHS ester groups
Similar protocols3 were used to coat both the larger Fe3O4@SiO2 NPs(100 nm diameter)
and smaller Fe3O4 @SiO2 NPs (20 nm diameter) with NHS ester groups.Briefly, Fe3O4@SiO2
NPs (100 nm diameter, 0.1 g) were resuspended in a solution containing ethanol (90 mL) and
nanopure water (10 mL) followed by sonication for15min. MPTMS (95 %, 1 mL) was added
drop wise and the mixture was mechanically stirred at room temperature for 15 hrs. The thiol
coated nanoparticles were separated from the solution using an external magnet, washed several
time with ethanol and air dried at room temperature.
The thiol coated Fe3O4@SiO2 NPs were treated with TCEP-HCl solution in water
(10mM) prior to NHS ester conjugation to cleave any disulfide bonds formed between surface
thiol groups. The NPs were washed multiple times with water, ethanol and acetonitrile to remove
excess TCEP. N-Succinimidyl 3-(2-pyridyldithio)-propionate (SPDP) was first dissolved in
anhydrous DMSO (10 mg/mL SPDP in DMSO) and then added to thiol coated NPs and stirred at
room temperature for 1 hr. The NHS ester coated NPs were magnetically separated, washed
several times with ethanol and dried under vacuum before use.

2.2. 5 Conjugation of dansylcadaverine to NHS ester modified Fe3O4@SiO2 MNPs
NHS ester coated Fe3O4@SiO2 MNPs (100 nm diameter, 7 mg) or smaller NHS ester
coated Fe3O4@SiO2 MNPs (20 nm diameter, 6 mg) were incubated with dansylcadaverine
(2mM, 1 mL in ethanol) in the dark at room temperature for 1 hr. The dansylcadaverine
conjugated MNPs were collected by an external magnet and washed repeatedly with dimethyl
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sulfoxide (DMSO), ethanol, and water. Dansylcadaverine modified MNPs were treated
withTCEP(50 mM) solution in water (300 µL) at room temperature for 1 hr. The cleaved product
(3-mercaptopropanamido dansylcadaverine, 3-MPA-Dansyl) was recovered by repeatedly
washing the MNPs and by magnetic separation. The supernatant and wash solutions were
combined and dried under vacuum. The cleaved 3-MPA-Dansyl samples were dissolved in 20:80
acetonitrile:water (1 mL) prior to HPLC analysis.

2.2. 6 Synthesis of 3-Mercaptopropanamido dansylcadaverine (3-MPA-Dansyl)
Dansylcadaverine(10 mg, 0.032 mmol, 2 equiv.) was added to a well stirred solution of
DTSSP (10mg, 0.016 mmol, 1 equiv.) in dichloromethane/methanol (10:1) and triethylamine
(4.5 µL, 0.032 mmol, 2 equiv.). The reaction mixture was stirred for 12 hours at room
temperature. After 12 hours, the solvent was evaporated under reduced pressure and the crude
product was dispersed in water (5 mL) and extracted with ethyl acetate (3×5 mL). The combined
organic extract was dehydrated by mixing with sodium sulphate and evaporated under reduced
pressure. The product was purified by flash chromatography technique using 50% ethyl
acetate/hexane to get white solid (5.22 mg, 0.0072 mmol, 45% yield). TCEP HCl (20.55 mg,
0.0822 mmol, 4 equiv) was added to a well stirred solution of the obtained product (15 mg, 0.02
mmol, 1 equiv) in methanol with 4-5 drops of water. The reaction mixture was stirred for 2 hours
at room temperature. After 2 hours, the solvent was evaporated under reduced pressure. Water (5
mL) was added to the crude product and extraction of crude product was carried out with ethyl
acetate (3×5 mL). The combined organic extract was dehydrated by mixing with sodium sulphate
and evaporated under reduced pressure to furnish solid product. (1.7 mg, 20% yield).
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2.2. 7 Characterization of 3-MPA- Dansyl
Excitation and emission spectra of 3-MPA-Dansyl were obtained using a
PerkinelmerLS55 fluorescence spectrometer with a pulsed Xe lamp as the light source. The
sample was dissolved in 20%acetonitrile-80% water and transferred to a 1-cm quartz cuvette.
The excitation and emission were scanned over ranges of 200-500 nm and 400-700 nm
respectively. 3-MPA-Dansyl was also analyzed by a Finnigan LTQ ion trap mass spectrometer
(Thermo Electron, San Jose, CA). The flow rate for direct infusion was set to 1 µL/min.
Electrospray capillary voltage was set to 2.65 kV with temperature at 200 °C. Mass
spectrometric analysis of 3-MPA-Dansyl showed the peak at m/z 424.1 Da which corresponded
to [M+H]+of 3-MPA-Dansyl.
NMR Chemical Shifts of 3-MPA- Dansyl:
1

H NMR (400MHz, CDCl3) = δ 1.23-1.44 (m, 6H), 2.60 (t, J = 7.2Hz, 2H), 2.86 (q, J = 6.4Hz,
2H), 2.88 (s, 6H), 3.03 (t, J = 6.4Hz, 2H), 3.13 (q, J = 6.0Hz, 2H) 5.35 (t, J = 6.0Hz, 1H), 6.27 (t,
J = 5.6Hz, 1H), 7.17 (d, J = 8.0Hz, 2H), 7.49-7.56 (m, 2H), 8.21 (d, J = 7.2Hz, 2H), 8.32 (d, J =
8.8Hz, 2H), 8.53 (d, J = 8.4Hz, 2H).

2.2. 8 HPLC instrumentation and chromatography conditions
An Agilent 1100 HPLC systems (Agilent, Santa Clara, CA) with 1100 series quaternary
gradient pump, vacuum degasser and HP 1046A fluorescence detector was used for all
measurements. Isocratic elution with a mobile phase of 80% acetonitrile and 20% water was
used for all measurements. The detector was set at 335 nm for excitation and 530 nm for
emission. A GRACE VisionHT™ C18 Classic 5µm 150 x 4.6 mm column (Grace, Columbia,
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MD) was used for all analyses at ambient temperature with a flow rate of 0.8 mL/min.
2.2. 9 Fluorescence microscopy imaging of dansylcadaverine modified Fe3O4@SiO2 MNPs
NHS ester modified Fe3O4 @SiO2 MNPs (100 nm diameter, 1 mg)were incubated at room
temperature with 1 mL of 2 mM dansylcadaverine in ethanol for 1 hr. The nanoparticles were
separated by a magnetic field and washed multiple times with DMSO, water and ethanol. The
fluorphore-conjugated magnetic nanoparticles were re-dispersed in ethanol (1 mL), and small
aliquots were transferred to a glass slide and air-dried in the dark prior to fluorescence
microscopy imaging. An Olympus IX 71 inverted fluorescence microscope with a high
performance 16 bit resolution, back illuminated CCD camera (Roper Scientific) and a 100 W Hg
lamp as the light source was used for the measurements. The fluorescence images were taken
through a 40X microscope objective with numerical aperture (NA) = 0.75. The filter cube of the
microscope contained a 450 ±10 nm band-pass excitation filter, a 505 nm dichroic mirror, and a
515-nm long pass emission filter.
A program run under MATLAB®37 was written for fluorescence intensity integration.
The fluorescence intensities of dansylcadaverine conjugated MNPs in a fluorescence microscope
image were calculated in two steps. First, the color image (red, green, blue) was converted to a
grayscale image. Second, the intensities of bright spots on this grayscale image were calculated
by adding the intensities of pixels together. In the grayscale image, the background pixels were
converted to black pixels. Therefore, the background was removed from the intensity integration.
The brightness of a pixel was normalized to the scale from 0 to 1.
2.2. 10 Fluorescence intensity calculations using MATLAB
The fluorescence images were processed in two steps. First, the color image (Figure
2.1A) was converted to a grayscale image (Figure 2.1B). In the second step, the intensity of the
38

grayscale image was calculated by integration of all pixels intensities. Since the background
pixels are black (Figure 2.1B) with the intensity value of zero, the total intensity of the image is
not affected by the background. The total intensity value, , for a 8-Bit grayscale image was
obtained as equation (1).

=

Where

(1)

is intensity of pixel

th

and 255 is the number of all pixels.

Figure 2.1: Conversion of RGB image (a) to grayscale image (b) in order to calculate the image intensity.

2.2. 11 Measurement of BSA conjugated to Fe3O4@SiO2 nanoparticles
Bovine serum albumin (BSA) solution (1 mL of 1 mg/mL) in phosphate buffered saline
(PBS, 10 mM, pH 7.4) was incubated with iodoacetamide (20 mM) in the dark at 37°C for 1 hr,
then the mixture was diluted with PBS to 0.5 mg/mL of BSA. Mixing of the NHS ester modified
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Fe3O4@SiO2 (100 nm diameter) MNPs with the BSA solution (0.5 mg/mL in PBS pH 7.4) was
performed according to Scheme2.3. The MNPs were washed several times with water and
acetonitrile (70%). All the washes were combined, centrifuged, dried under vacuum, and redissolved in 10 µL of nanopure water. The un-conjugated BSA in the combined washes was
quantified by using a BCA according to the protocol provided by the manufacturer. The amount
of BSA conjugated to the MNPs labelling reagent was calculated by subtraction of unconjugated BSA from the initial amount of fresh BSA used for labelling reaction.

BSA

BSA

BSA

NHS ester modified
NPs + BSA

Dried NHS ester modified
NPs

BSA
+
NPs

BSA
+
NPs

BSA
+
NPs

NHS ester modified
NPs

Schematic 2.3: Mixing method for labeling BSA by NHS ester modified Fe3O4 @SiO2 MNPs.

2.3 Results and discussion
The size and shape of Fe3O4@SiO2 MNPs employed in this study was significantly
improved compared to that of the Fe3O4@SiO2 MNPs in previous proof of concept study
performed in our lab.33 Although Fe3O4 @SiO2 MNPs with irregular shapes were
40

superparamgnetic, it was difficult to estimate the surface area of these particles as well as the
number of intermediate functional groups (e.g. primary amine, thiol) per MNP. Additionally,
MNPs with irregular shapes might have less binding sites that are sterically accessible for the
approaching protein molecules . This affects the number of protein molecules that could bind to
the MNPs. TEM analysis confirmed the uniformity in size and shape for both larger
Fe3O4@SiO2MNPs (100 nm diameter) and smaller Fe3O4@SiO2 MNPs (20 nm diameter). Such
size and shape uniformity, facilitated improved characterization of the surface modified MNPs.

2.3. 1 NHS ester conjugated Fe3O4@SiO2 MNPs
The spherical and uniform nature of the magnetite core of silica coated MNP with
diameters of 80 ± 5 nm (Figures 2.2a) and Fe3O4@SiO2 MNPs with 100 ± 10 nm diameters was
confirmed by TEM image analysis (Figures 2.2 a). Smaller Fe3O4 @SiO2 MNPs (20 nm diameter,
Figure 2.2b) with improved uniformity in size and shape were prepared and employed in this
study, however the majority of the experiments were performed on larger MNPs. The silica
coating improved aqueous stability , protected the MNPs from oxidation and reduced nonspecific
interactions with ligands.
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Figure 2.2: TEM image of a) Fe3O4@SiO2nanoparticles (100 nm diameter) and b)
Fe3O4@SiO2nanoparticles (20 nm diameter). MNPs were uniform in size and shape, and well dispersible
in aqueous solvents.

MPTMS was used to further functionalize the 100 and 20 nm Fe3O4@SiO2 MNPs with
thiol groups. The theoretical number of thiol groups that could be conjugated to the surface of
each 100 nm Fe3O4@SiO2 MNP was calculated to be about 105. The estimation was based on the
following parameters: density of MNPs (4.5 g/cm3), total mass of MNPs (1 mg), bond length of
Si-O (171 picometer), and bond angle of O-Si-O (109.5˚). To determine the theoretical number
of surface groups after modification ,the total surface area of the particles and the estimated
surface area required per MPTMS were calculated. Based on the theoretical number of thiol
groups on MNPs surface, the amount of SPDP for free thiol group conjugation could be
estimated. Based on these calculations, 1 mg of 100 nm Fe3O4@SiO2 MNPs should be able to
react with 22 µg of SPDP.
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2.3. 2 Fluorescence-based quantification of active NHS ester groups on the surface of
Fe3O4@SiO2 MNPs
Since dansylcadaverine contains a primary amine group similar to that in the side chain
of the amino acid lysine, it can be covalently attached to NHS ester conjugated Fe3O4@SiO2
MNPs via a nucleophilic substitution reaction between the NHS ester and the primary amine. A
disulfide bond is incorporated in the spacer/linker between the fluorophore moiety and the
Fe3O4@SiO2 MNPs moiety (Scheme2.4). The fluorophore moiety can be cleaved from the
modified Fe3O4@SiO2 MNPs by reductive cleavage of the disulfide bond in the spacer/linker.
The fluorescent dansylcadaverine serves as an indicator for quantification of NHS ester groups
on the surface of Fe3O4@SiO2 MNPs.
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Schematic 2.4: A cleave-analyze approach for quantification of 3-MPA-Dansyl released upon cleaving
disulfide bond between nanoparticles and dasnylcadaverine.
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2.3. 3 Quantification of NHS ester groups by cleave-analyze approach
3-MPA-Dansyl was released by reductive cleavage of the disulfide bond in the linker
between the dansylcadaverine moiety and the Fe3O4@SiO2 MNPs (structure in Scheme 2.4) and
analyzed by HPLC with fluorescence detection. HPLC analysis also facilitated the separation of
TCEP, which is reported to affect the fluorescence of various fluorophores.40 In order to
accurately quantify dansylcadaverine released from the fluorophore modified Fe3O4 @SiO2
MNPs, the calibration standard 3-MPA-Dansyl(Scheme2.5), was synthesized and characterized
by fluorescence spectroscopy (Figure 2.3), mass spectrometry and NMR. The synthesized
calibration standard (3-MPA-Dansyl) showed the same retention time as that of 3-MPA-Dansyl
released from MNPs but eluted from the HPLC column faster than unmodified dansylcadaverine
(Figure 2.4).

Excitation

Emission

Figure 2.3: Fluorescence spectrum of 3-MPA Dansylcadaverine Excitation: 335 nm andEmission: 530
nm.
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Figure 2.4: Chromatogram obtained by HPLC-fluroescence analysis of (a) Control, (b) dansylcadaverine
(5µM) (c) 3-MPA-Danysl (20µM) and (d) 3-MPA- Dansyl released from 7 mg of Fe3O4@SiO2 MNPs
(100nm in diameter) upon cleaving the disulfide bond. For all samples the injection volume was 100µL.
The isocratic elution with mobile phase of 80% ACN and 20% H2O was performed for all samples. The
control sample was prepared by reacting thiol coated MNPs (7 mg) with dansylcadaverine.

Based on the following parameters ,the number of dansylcadaverine molecules per
Fe3O4@SiO2 MNP was estimated: size of the nanoparticle (determined by TEM), density of
MNPs (estimated based on the structure of Fe3O4@SiO2, i.e., the size of magnetite core and the
thickness of the silica coating layer), and the amount of 3-MPA-Dansyl released from
dansylcadaverine conjugated Fe3O4@SiO2 MNPs. For the smaller Fe3O4 @SiO2 MNPs (20 nm
diameter, 6 mg), the amount of conjugated dansylcadaverine was determined by HPLC to be

47

2.4× 10-7 mol. The number of dansylcadaverine molecules per MNP was calculated based on the
following assumptions. The density of 20 nm diameter Fe3O4@SiO2 MNPs was estimated to be
2.5 g/cm3 according to the density values of Fe3O4 (5.17 g/cm3) and SiO2 (2.2 g/cm3).41
Consequently, 6 mg of these MNP contained approximately 5.62 × 1014 particles, the average
number of dansylcadaverine conjugated to one nanoparticle was about 2.6 × 102, and the number
of conjugated dansylcadaverine per milligram of 20 nm MNPs was 2.4 × 1016. Similarly, it can
be estimated for 100 nm Fe3O4 @SiO2 MNPs, the average number of dansylcadaverine
conjugated to one nanoparticle surface was about 3.4 × 103, and the number of conjugated
dansylcadaverine per milligram of 100 nm MNPs that approximately contained 4.27 × 1011
particles, was 1.4 × 1015. Assuming a 1:1 stoichiometry and optimum efficiency, the number of
NHS ester groups on the MNP surface should be equal to the number of released 3-MPA-Dansyl
molecules. The actual number of NHS ester groups on each 100 nm Fe3O4 @SiO2 MNP was less
than the theoretical maximum number of thiol groups that could attach to the MNP surface
(~105).Steric hindrance and hydrolysis of NHS ester groups in contact with moisture in the
solvent or air between preparation of the particles and binding to the fluorophore are two
important factors that may contribute to the observed difference in conjugation efficiency.

2.3. 4 Semiquantitaive fluorescence microscopic characterization of dansylcadaverine
modified Fe3O4@SiO2 MNPs
As a rapid and sensitive technique, fluorescence microscopy was used for qualitative and
semi-quantitative characterization of active NHS ester groups covalently attached to
dansylcadaverine. The presence of NHS esters on the surface of Fe3O4@SiO2 MNPs was
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confirmed by detecting the green fluorescence of dansylcadaverine conjugated Fe3O4@SiO2
MNPs using a fluorescence microscope (Figure 2.5a). No fluorescence signal was detected for
thiol coated Fe3O4@SiO2 MNPs that were used as a negative control (i.e. no dansylcadaverine)
under the same conditions (data not shown). By measuring the fluorescence intensity of
microscope images, the quantity of dansylcadaverine conjugated to NHS ester coated
Fe3O4@SiO2 MNPs can be calculated. Even though similar fluorescence image processing
software were reported in the literature,42,43 the fluorescence image processing program
employed in this study was developed independently and run in MATLAB environment (Figure
2.1). As we see in Figures 2.5a and 2.5b, the fluorescence intensities increased with the
increasing amount of dansylcadaverine coated Fe3O4@SiO2 MNPs. To prove that the fluorophore
molecules were immobilized onto the MNPs surface only through covalent attachment , a control
experiment (Figure 2.5 a7) was performed in which the NHS groups on the surface of
Fe3O4@SiO2 MNPs were hydrolyzed by incubation. The carboxylic acid coated Fe3O4@SiO2
MNPs (product of NHS ester hydrolysis) were then treated with dansylcadaverine, followed by
fluorescence microscopy observation of the extensively washed MNP. No fluorescence was
detected for such hydrolyzed MNPs incubated with dansylcadaverine(Figure 2.5 a7) . This
observation confirmed that nonspecific adsorption of fluorophore to the surface of Fe3O4@SiO2
MNPs was minimal.
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Figure 2.5: Fluorescence micrographs of Fe3O4@SiO2 MNPs labeled with dansylcadaverine. a)
Micrographs (a1-a6) represent fluorescence images obtained from 5, 10, 20, 40, 80 and 160 µg of
dansylcadaverine labeled Fe3O4 @SiO2 MNPs. The control sample (a7, 20µg) was prepared by reacting
the hydrolyzed NHS ester coated Fe3O4 @SiO2 MNPs with dansylcadaverine. The fluorescence intensity
on a7 is below detection limit. b) Integrated fluorescence intensities of the images in (a) were plotted
against quantity of MNPs.

The fluorescence microscopic method employed for detection of dansylcadaverine
coated Fe3O4@SiO2 MNPs, could be considered as semi-quantitative method since it revealed
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the trend of elevated fluorescence intensities with the increasing amount of fluorophore coated
MNPs. We were also able to detect the fluorescence signal from 5 µg of dansylcadaverine coated
Fe3O4@SiO2 MNPs using the abovementioned highly sensitive fluorescence microscopy
approach. Compared to the HPLC method that was employed for accurate quantification of NHS
ester groups on Fe3O4@SiO2 MNPs surface, the fluorescence microscopy approach is more
convenient for monitoring the incorporation of NHS ester group on nanoparticle surface. For the
application of NHS ester coated magnetic nanoparticle reagent in labelling the exposed lysine
residues of native proteins, the presence of NHS ester on Fe3O4@SiO2 MNPs surface is
essential.33

2.3. 5 Labeling efficiencies of exposed lysine residues in native protein by NHS ester
conjugated Fe3O4@SiO2 MNPs
The reaction of primary amine groups in proteins with NHS/sulfo-NHS ester has been
extensively used for protein conjugation.4 The conjugation reaction can be done at room
temperature in aqueous solution, which allow us to detect exposed lysine residues in the native
structures of proteins. A large volume of solvent is required to re-disperse the bulky MNPs
labelling reagent compared to equivalent amount of small molecule labelling reagents such as
sulfo-NHS-SS-biotin. This requirement on solvent would results in dilution of protein in the
reaction system and reduced the primary amine labelling efficiency. For the same initial amount
of BSA (100 µg), a larger quantity of NHS ester coated MNPs (7 mg) dissolved in larger volume
of the solvent (400 µL PBS), captured a smaller amount of protein (27 µg), compared to a
smaller quantity of MNPs in a smaller volume of solvent (3 mg MNPs in 200 µL PBS) that
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captured 52 µg of BSA. If the protein concentration in aqueous solvent was below 0.5 mg/mL,
the efficiency of the reaction between the primary amine and the NHS ester groups (conjugated
to the MNPs) was dramatically decreased due to the hydrolysis of NHS/sulfo-NHS ester.
To solve the above mentioned issues, a special sample mixing method was employed in
labelling the exposed lysine residues of native BSA with NHS ester coated Fe3O4@SiO2
MNPs(Scheme2.3). Instead of mixing the NHS ester coated Fe3O4@SiO2 MNPs with BSA in
one step, the MNPs were divided to smaller portions and added to the BSA solution separately.
After the first addition of the MNPs, the labelling reaction was allowed to proceed for 30
minutes followed by addition of the remaining fresh NHS ester coated MNPs with an additional
30 minutes of shaking. The reaction volume was kept minimal in order to maintain the initial
high concentration of BSA. The addition of fresh NHS ester coated Fe3O4@SiO2 MNPs allows
us to label those lysine residues that were not modified in the first step due to hydrolysis of NHS
ester groups.
Two types of experiments were designed and performed to investigate the effect of
quantity of MNPs and proteins on labelling efficiency. In the first set of experiments, the same
amount of MNPs was reacted with different amounts of BSA. The second set of experiments
were performed by mixing the same amount of BSA with different amounts of MNPs. The above
mentioned sample mixing methods was used in both experiments to mix MNPs with BSA, and
BCA assay was performed to measure the unbound BSA. In order to understand the effects on
labelling efficiency either by increasing the ratio of BSA/MNP (Figure 2.6a) or by increasing the
ratio of MNP/BSA (Figure 2.6b), the amounts of BSA conjugated to MNPs were compared in
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both experiments. With increasing amount of BSA, the quantity of BSA conjugated to the NHS
ester coated Fe3O4@SiO2 MNPs (0.5 mg) increased until reaching a maximum at16 µg of BSA
added. After this maximum point, the quantity of captured BSA did not change by adding more
BSA to the reaction, indicating that 0.5 mg of labelled MNP can bind a maximum of 16 µg of
BSA. A similar pattern was observed in the second set of experiments, where an increase in the
amount of BSA conjugated to Fe3O4@SiO2 MNPs reached to plateau once all the available BSA
were labelled. The results from these experiments were in agreement with the constant MNP
experiment, with 0.5 mg of labelled MNPs binding about 18 µg of protein. The molar ratio of
BSA to available NHS ester groups determined by fluorescence quantification was 1:12.
In case of increasing MNP/BSA ratio ( the first type of experiment), few MNPs can be
conjugated to one BSA molecule when the number of BSA molecules was small. As we increase
the amount of BSA, one magnetic nanoparticle can be conjugated to several BSA molecules. In
the second type of experiment that involved increasing BSA/MNP ratio, when amount of MNPs
were low, some of the BSA molecules could have multiple sites labelled, and some might have
one site labelled, and some might not be labelled at all. In this case, it is also possible that one
MNP could label several BSA molecules. By increasing the amount of MNPs, more sites in one
BSA molecule could be labelled , but due to large number of bulky MNPs present in the system
,the average number of BSA molecules attached per magnetic nanoparticle could be reduced.
The sample mixing method described previously, might not be required when the BSA/MNPs
ratio was large due to the fact that BSA concentration was high enough for most of the MNPs to
be conjugated by at least one BSA molecule. The first set of experiments (increasing MNP/BSA
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ratio) could be used as an effective approach to label multiple sites in one protein molecule. On
the other hand, the second set of experiments (increasing BSA/MNP ratio) can be employed
when preserving the native structure of the protein during the labelling process is highly desired.

Figure 2.6: Quantitative study of labeling BSA by NHS ester modified Fe3O4@SiO2MNPs. The amount
of BSA conjugated to the NHS ester coated Fe3O4@SiO2MNPs was calculated by subtracting the amount
of remaining BSA from the initial amount of BSA. In the series of experiments presented in Fig. 2.6a, the
amount of NHS ester coated Fe3O4@SiO2 MNPs (0.5 mg) was kept constant and amount of BSA was
varied (20,40,60,80 and 100 µg). In Fig. 2.6 B, the quantity of BSA (20 µg) conjugated was kept constant,
and the quantity of NHS ester modified MNPs was varied (0.05, 0.1, 0.5, 1 and 3 mg).
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2.4 Conclusions
The reactivity of NHS ester groups conjugated on Fe3O4@SiO2 MNPs surface towards
primary amine containing molecules such as the fluorophore dansylcadaverine provides the
possibility of qualitative and quantitative characterization of the amount of NHS ester groups
immobilized on Fe3O4@SiO2 MNPs surfaces. Accurate quantification of NHS ester groups was
performed by HPLC analysis of modified fluorophore that was detached from Fe3O4@SiO2
MNPs via reductive cleavage of disulfide bond in the linker between the fluorophore and MNPs.
On the other hand, fluorescence microscopy was employed as a fast and sensitive approach for
direct measurement of fluorophore conjugated Fe3O4@SiO2 MNPs ,and to determine if NHS
ester groups were immobilized on the magnetic nanoparticle surface. In case of using bulky
labelling reagents such as NHS ester coated Fe3O4@SiO2 MNPs, maintaining the concentration
of fresh NHS ester groups in the reaction system is very important to increase the labelling
efficiency. This can be achieved by adding multiple doses of NHS ester coated MNPs to each
aliquot of protein during the labelling reaction. In case of labelling minimum sites in a protein of
high concentration, maintaining the concentration of fresh NHS ester groups may not be
necessary. However, it is critical to maintain the concentration of fresh NHS ester groups if
labelling as many sites as possible in a protein with multiple sites or protein mixtures such as a
cell surface proteom is desired.
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Chapter 3
Solvent Exposed Lysine Residues of Native Apolipoprotein B-100

3.1 Introduction
Low density lipoproteins (LDL) which is also referred to as 'bad cholesterol' transports
cholesterol in blood and interstitial fluids. Elevated levels of LDL and other lipoproteins
containing apolipoprotein B-100 (apoB-100) is a major cause of pathogenesis of atherosclerosis.
LDL particles usually range from 18-30 nm in diameter,1, 2and contain variable number of lipids
with one molecule of apoB-100.3, 4The hydrophilic core of LDL is surrounded by hydrophobic
phospholipids and fatty acids. The protein molecule provides stability to structure of lipids and
are responsible for recognition of cell surface receptors present on lipid molecules. In addition to
a single apoB-100 molecule, LDL contains linoleic acid, esterified and non-esterified cholesterol,
triglycerides, phospholipids containing phosphatidylcholine and sphingomyelin.5 The variability
of lipids adds a great amount of heterogeneity to the structure of LDL, which makes it a
challenging task to elucidate the structure of ApoB.
ApoB-100 is a large hydrophobic glycoprotein containing 4536 amino acids (mature
form). ApoB exists in two isoforms; apoB-100 and apoB-48 of which apoB-48 lack the receptor
binding domain and cannot bind to lipid receptor domain. However, since apoB-48 is produced
after RNA editing of apoB-100, both of these isoforms share similar N-terminal sequence. Cryoelectron microscopic results determined the length of detergent solubilized apo B-100 to be
around 650 Å.17 The large size and insolubility in aqueous solvents makes it difficult to obtain
structural information about apoB-100. Great amount of efforts were poured into studying the
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receptor binding domains of apoB-100 interacting with lipids. Circular dichroism (CD) and
helical wheel analysis shade light on the presence of 25% α helical content,7 role of
intramolecular disulfide linkage in conformation of ApoB-1008 and the lipid associating motifs
of ApoB-100.6 Infrared spectroscopy and CD analysis of ApoB-100 also confirmed the presence
of β sheet structure in ApoB-100. Using a computer program called LOCATE, Segrest et al.
proposed a pentapartite structure of ApoB-100 containing two β strands alternating with two α
helices and and N-terminal α helical domain.10 Further, Chen et al suggested the parallel
orientation of β sheets with phospholipid monolayer of LDL using FTIR, which might contribute
to the high affinity of ApoB-100 to lipid receptors.9 The interaction of ApoB-100 with lipid
receptors is highly influenced by the presence of solvent exposed lysine and arginine residues.11
Use of trypsin to release the surface exposed portion of apoB-100 may provide information about
the composition of amino acids present on the surface of apo B-100. Fractionation of trypsin
accessible peptides of apoB-100 coupled with two dimensional fingerprinting and amino acid
analysis divided trypsin releasable peptides into four categories according to size, amino acid
composition and C-terminal residues. All the four categories showed abundance of arginine and
lysine residues along with relative positioning of arginine and lysine residues on the surface of
apoB-100.18 Yang et al. used trypsin to release lipid associating peptides of apoB-100 and
Edman degradation to identify sequence of 13 trypic peptides in 5 domains based on their trypsin
releasibility.20
Solvent exposed lysine residues were chemically modified by 13C methyl groups
followed by NMR characterization. NMR technique revealed presence of 53 active and 172
normal lysine residues on the solvent exposed surface of ApoB-10013 The 1D NMR,15, 16 and 2D
NMR14 was also used to detect different populations of solvent exposed lysine groups of apoB.
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The NMR studies were focused on determination of number of active solvent exposed lysine
residues irrespective to the position on the lysine residues located on the exposed surface of apo
B-100. Chemical modification/labeling of active sites of proteins coupled with mass
spectrometry has been preferred to study tricky proteins which are not suitable for NMR and Xray crystallography due to size, purification, hydrophobic nature and inability to crystallize.
Posttranslational modification of LDL which include oxidative modifications of tryptophan, 19
phenylalanine and proline were reported earlier. In our lab, oxidation of lysine, phenylalanine,
proline, tryptophan and histidine amino acids upon exposure to hydroxyl radicals, peroxynitite
and sodium hypochlorite was studied along with the position of modified amino acids in
peptides. The modification was carried out prior to delipidation process and dialysis was used to
remove lipids before LC-MS/MS analysis.21, 22 However, it has been a challenging task to ensure
the modification of solvent exposed amino acid residues due to ability of small chemical
modification reagents to cross the lipid bilayer and modify the internal amino acid residues
embedded inside the structure of apoB-100.
In order to ensure the specific modification of solvent exposed peptides, we have utilized
the large size of silica coated iron oxide magnetic nanoparticles (Fe3O4@SiO2 MNPs) which
carries NHS ester group to modify solvent exposed free amine groups of apoB-100.23 NHS ester
modified Fe3O4@SiO2 MNPs contain a cleavable disulfide bond to isolate MNPs upon labeling
and introduces a distinct mass shift on lysine residues which helps the identification of labeled
peptides using mass spectrometry. In this work, we extend the application of NHS ester modified
Fe3O4@SiO2 MNPs to label the solvent exposed amine groups of native apoB-100. The
modification was performed at room temperature and in physiological conditions to maintain the
native structure of apo B-100. Upon labeling, samples were delipidated using SDS treatment and
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magnetic separation allowed the efficient and quick removal of SDS from the labeled apoB-100.
After tryptic digestion, disulfide bond was cleaved in aqueous conditions to elute labeled
peptides. LC-MS/MS analysis identified 28 solvent exposed peptides of native apoB-100.

3.2 Materials and Methods
Ferric (III) chlroride hexahydrate, (FeCl3.6H2O, 99%), dimethyl sulfoxide (DMSO,
anhydrous), (3-mercaptopropyl)trimethoxysilane (MPTMS, 99%), tetraethylorthosilicate (TEOS,
99%), sodium dodecyl sulfate (SDS) and ammonium bicarbonatewere purchased from Sigmaaldrich (St. Louis, MO). Trisodium citrate, anhydrous, 99%, and sodium acetate, anhydrous, 99%
were purchased from Alfa Aesar (Ward Hill, MA). Sodium citrate dihydrate was purchased from
J. T. Baker Chemicals (Center Valley, PA). Ammonium hydroxide, was purchased from EMD
Millipore (Billerica, MA). Ethylene glycol was purchased from VWR internationals (Radnor,
PA). Succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate (LC-SPDP) was purchased
from Proteochem (Loves Park, IL,USA). Human low density lipoprotein (LDL) was purchased
from Calbiochem (Billerica,MA) and Biovendor (Asheville, NC).Trypsin was purchased from
Promega (Madison, WI). Tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) was
purchased from Amresco (Solon, OH).Phosphate buffered saline (PBS) was purchased from
Calbiochem (Billerica,MA). Ethanol was purchased from Pharmco-AAPER (Brookefield,CT).
Nanopure water (18.2 MΩ) was used for all experiments.
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3.3

Synthesis of silica coated iron oxide magnetic nanoparticles (Fe3O4@SiO2 MNPs)
Supeparamagnetic nanoparticles (Fe3O4) were prepared by the hydrothermal method and

then coated with silica (Fe3O4@SiO2) using the modified Stober method as described in details
in Chapter 2.

3.4

Surface functionalization of Fe3O4 @ SiO2 MNPs with NHS ester groups
The synthesized Fe3O4@SiO2MNPs were coated with thiol groups using MPTMS and

then treated with TCEP prior to NHS ester coating as described previously (Chapter 2). The thiol
coated MNPs (5 mg, 100 nm diameter) were dispersed in 200 µL of ethanol and sonicated for 1
min.A solution of Succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate (LC-SPDP, 8
mg) in anhydrous dimethyl sulfoxide (DMSO, 50 µL) was added to the nanoparticles
suspension. The mixture was stirred at room temperature for 90 min and the NHS ester coated
MNPs were collected by magnetic separation and then washed several times with ethanol to
remove unreacted LC-SPDP.
To evaluate the success of NHS ester coating, 1mg of the prepared NHS ester modified
nanoparticles were dispersed in 100 µL of 0.5 mM solution of dansylcadaverine in ethanol and
the mixture was stirred at room temperature for 90 min. The fluorophore coated MNPs were
washed several times with DMSO, ethanol and water to remove unreacted fluorophore.
Fluorophore-nanoparticle conjugates were re-disperesed in 50 µL of ethanol. 10 µL of this
solution was transferred to a microscope slide and observed under Olympus IX 71 inverted
fluorescence microscope with a high performance 16 bit resolution, back illuminated CCD
camera (Roper Scientific) and a 100 W Hg lamp as a light source.
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3.5 Labeling solvent exposed lysine groups of ApoB-100 in native human low density
lipoprotein (LDL) using NHS ester functionalized Fe3O4@SiO2 MNPs
The NHS ester modified Fe3O4@SiO2MNPs were re-dipersed in 200 µL of ethanol and
equally distributed among four micro centrifuge tubes (1.5 mL). The solvent (ethanol) was then
removed under vacuum.
Low density lipoprotein solution (protein concentration of 5 µg/µL, 20 µL) was diluted to
80 µL using phosphate buffered saline (PBS, 100 mM) with iodoacetamide (final concentration
of 30 mM). The protein solution was mixed on a mechanical stirrer in dark at 37°C for one hour.
The LDL solution was then distributed between four centrifuge tubes each containing 1mg of
NHS ester coated nanoparticle. The nanoparticle - LDL suspensions were mixed for 30 min,
combined and then mixed for another 60 min. The unreacted NHS ester groups were quenched
using tris-HCl (100 µL, 1M). LDL- MNPs conjugates were separated using a magnet and
washed multiple times with 2% SDS, 20, 50 and 70 % acetonitrile (ACN) in water and finally
water containing IAA (30 mM).
The ApoB - MNPs conjugates were dispersed in methanol/ammonium bicarbonate
mixture (3: 2, v/v, 1mL) containing IAA (30mM) followed by addition of trypsin (14 µL of 0.5
µg /µL solution, 7 µg). The tryptic digestion was carried out at pH 8 for 15 hrs at 37°C. The
tryptic peptides conjugated to the MNPs were collected by magnetic separation and the
supernatant was acidified and stored at -20°C for further analysis. The MNPs were washed with
20, 50 and 70% ACN in water and finally nanopure water multiple times.
To release the trypitc peptides from Fe3O4@SiO2 nanoparticles, the peptide-MNPs
conjugates were dispersed in TCEP solution in water (1mL, 30 mM) and the suspension was
mixed for 1hr at room temperature. The supernatant containing cleaved modified peptides was
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collected and the Fe3O4 @SiO2 nanoparticles were washed multiple times with 20, 50 and 70%
ACN in water. The supernatant and washes were combined and then dried under vacuum. The
peptides were then re-suspended in 500 µL of water and the sample was desalted using C18 spin
columns (Pierce, Rockford, IL) and dried under vacuum. The peptides were re-suspended in 50
µL of water/ acetonitrile / formic acid (92: 5: 3, v/v) prior to LC-MS/MS analysis.

3.6 LC-MS/MS and data analysis of ApoB-100 peptides labeled with NHS ester modified
Fe3O4@SiO2 MNPs

All Mass spectrometric analyses were performed using an Agilent 1200 HPLC system
and an Agilent 6520 Q- TOF tandom mass spectrometer (Agilent Thechnologies, Santa Clara,
CA) coupled with a chip cube interface. Peptide sample (2 µL) was loaded to the HPLC-Chip
system (160 nL enrichment column , 150 mm analytical column packed with C18, 5 µm beads
with 300 A° pores) using a capillary pump at 4 µL/min flow rate. The peptides were then
separated in the analytical column using a nano pump at a flow rate of 600 nL/min. The MS ion
source was operated at 300°C with nitrogen as drying gas at flow rate of 5 L/min and a
fragmentor voltage of 175 V. Nitrogen was used as the collision gas and the collision energy
varied as a function of mass and charge using a slope of 3.7V/100 Da and an offset of 2.5V. The
reference compounds with the mass of 322.048121 and 1,221.990637 Da were constantly
infused into the ion source during the analysis. All analyses were performed in positive ion
mode. Table 3.1 shows solvent gradient used for LC-MS/MS analysis.
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Time

Solvent A (%)

Solvent B (%)

0.00

97

3

2.00

90

10

15.00

70

30

20.00

0

100

22.00

0

100

25.00

97

3

Table 3.1: Solvent gradient used for analysis of tryptic digests of labeled apoB-100. Solvent A: water
(100%), formic acid (0.1%). Solvent B: Acetonitrile: water (90:10), formic acid (0.1%).

The acquired MS/MS spectra were processed using PEAKS software (Bioinformatics
Solutions Inc,Ontario, Canada). A full length cDNA sequence of Apo B-100 (accession #
P04114) was used in database search. Trypsin was selected as proteolytic enzyme and the
number of missed cleavage sites was set to three. The search parameters were set as follow:
differential mass increase of 201.28 Da for lysine residues, 57.07 Da for carbamidomethylated
cysteine residues and 15.99 Da for oxidation of methionine residues. The presence of b and y
ions for the peptides with high matching scores was confirmed by manual examination of MS
/MS spectra.
3.7

Results and Discussion

3.7.1 Synthesis of NHS ester functionalized Fe3O4@SiO2 MNPs
The Fe3O4 MNPs (80 nm diameter) were prepared using hydrothermal method, coated
with silica shell by modified Stober method and finally functionalized with thiol groups using
MPTMS as described in details previously (Chapter2). The synthesized thiol coated
Fe3O4@SiO2were approximately 100 nm in diameter, spherical in shape (confirmed by TEM)
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and well- dispersible in both aqueous and organic solvents. LC-SPDP was used to further
decorate the surface of thiol coated MNPs with NHS ester groups via disulfide exchange
reaction. To confirm the successful NHS ester functionalization, Dansylcadaverine was
conjugated to the surface of nanoparticles through the amide bond formation between the amine
group of fluorophore and the NHS ester moiety on the nanoparticles. The naoparticlesfluorophore conjugates were extensively washed with different solvents (DMSO, water and
ethanol) to ensure the removal of unreacted flourophore and then observed under the
fluorescence microscope. The green florescence of dansylcadaverin proved the presence of NHS
ester groups on the surface of nanoparticles.
3.7.2 Labeling solvent exposed amine groups of ApoB-100 in native human LDL using
NHS ester modified Fe3O4@SiO2 MNPs
The main steps for covalent modification of solvent exposed lysine groups of ApoB-100
using NHS ester modified Fe3O4 @SiO2 labeling reagent were summarized in Figure 3.1. The
quantity of NHS ester coated Fe3O4@SiO2MNPs for labeling specific amount of ApoB was
calculated based on the accurate quantification of NHS ester groups on the surface of MNPs
presented in Chapter 2. To preserve the native structure of LDL, the labeling reaction was
performed at room temperature and in aqueous-based buffer solution (PBS, pH 7.5). Cysteine
residues of ApoB were alkylated using iodoacetamide prior to labeling reaction to ensure that the
disulfide linkage between the NHS ester groups and MNPs stays intact. The concentration of
protein solution was kept very high during the conjugation reaction to minimize the chance of
NHS ester hydrolysis and improve the efficiency of the conjugation reaction. Tris HCl was used
to quench unreacted NHS ester groups prior to delipidation and digestion of protein. This step is
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necessary to prevent modification of those lysine groups which became accessible to the labeling
reagent during the lipid removal or digestion process.
The LDL - MNPs conjugates can be washed several times with a variety of solvents to
efficiently remove lipids associated with ApoB-100. Compare to conventional time consuming
and tedious methods for delipidation of membrane or lipid bound proteins (such as gel based
methods), magnetic separation provides fast and easy lipid removal. Different solvents
(chloroform, isopropyl alcohol, methanol, acetone, etc) or solvent combinations (chloroform
/diethyl ether/ water, chloroform/ methanol, etc) have been used for lipid removal which were
not found to be effective. In this case, the efficiency of protein digestion decreases dramatically
since lipid-bound protein is not accessible to the proteolytic enzyme and the generated peptides
usually have poor solubility and a high tendency to aggregate. The efficient delipidation was
achieved using 3% SDS followed by several washes with 20-70% ACN solution in water.
The magnetic separation also eliminated the need to perform commontime consuming
procedures such as dialysis to remove surfactant from protein solution. Due to strong
magnetization of nanoparticles, the protein-MNPs conjugates can be washed several times with
different solvents to quickly, simply and efficiently remove SDS prior to proteolytic digestion.
The efficient removal of detergent is crucial to maintain the activity of proteolytic enzymes such
as trypsin. Additionally, the presence of SDS in peptide solution is highly detrimental to MS
analysis since it can suppress the ionization of peptides.
After tryptic digestion of ApoB which was covalently bound to MNPs, the MNP-tryptic
peptide conjugates were collected by magnetic separation and extensively washed to remove
those peptides that are nonspecifically adsorbed on the surface of nanoparticles. Labeled peptides
were finally released from the surface of MNPs by reductive cleavage of the disulfide bonds
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between the peptides and MNPs. After magnetic separation of nanoparticles, the supernatant
containing the labeled tryptic peptides was desalted and then analyzed by LC-MS/MS.

Figure 3.1: Labeling surface exposed lysine residues of apoB-100 in intact LDL using NHS ester
modified Fe3O4@SiO2 MNPs.

Labeling surface exposed primary amine groups in ApoB-100 with the NHS ester coated
MNPs caused a 201.28 Da mass shift for lysine residues. LC-MS/MS analysis of tryptic digests
of ApoB-100 generated 28 MS/MS spectra corresponding to 28 labeled peptides which we
believe are located on the surface of intact LDL particles. Table 3.2 presents the amino acid
sequence of the labeled peptides as well as the exact position of amino acids in the full length
sequence of human apoB-100.
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Labeled peptides

Peptide sequence

- log p

1078-1089

(R)VNDESTEGK(+201.28)TSYR(L)

90.02

28-45

E(+201.28)EEM(+15.99)LENVSLVCPK(D)

78.44

3235-3244

(K)AEK(+201.28)SHDELPR(T)

73.4

3521-3537

(R)SSVK(+201.28)LQGTSK(I)

71.7

2695-2705

(R)DLK(+201.28)VEDIPLAR(I)

68.44

3508-3527

(R)EYSGTIASEANTYLNSK(+201.28)STR(S)

68.19

208-219

(R)DLGQCDRFK(+201.28)PIR(T)

64.85

3936-3946

(K)IEDGTLASK(+201.28)TK(G)

62.75

3498-3507

(K)GDVK(+201.28)GSVLSR(E)

59.26

288-297

(K)LEDTPK(+201.28)INSR(F)

58.58

116-128

(K)TK(+201.28)NSEEFAAAMSR(Y)

57.33

1296-1308

(K)IEIPLPFGGK(+201.28)SSR(D)

56.4

1120-1128

(K)IK(+201.28)GVISIPR(L)

55.49

743-760

(K)DDK(+201.28)HEQDM(+15.99)VNGIM(+15.99)LSVEK(L)

52.54

1309-1317

(R)DLK(+201.28)MLETVR(T)

47.5

1692-1702

(R)EHNAK(+201.28)FSLDGK(A)

47.07

1853-1867

(K)ADTVAK(+201.28)VQGVEFSHR(L)

45.85

3207-3212

(R)HFEK(+201.28)NR(N)

44.12

1287-1295

(K)YTLNK(+201.28)NSLK(I)

43.9

764-774

(K)DLK(+201.28)SK(+201.28)EVPEAR(A)

40.5

3156-3163

(K)TGLK(+201.28)EFLK(T)

40.08

2140-2147

(K)EK(+201.28)LTALTK(K)

38.34

1636-1646

(K)INSGAHK(+201.28)ATLR(I)

37.84

4036-4044

(K)LTIFK(+201.28)TELR(V)

36.13

4479-4486

(K)SQAIATK(+201.28)K(I)

33.74

2003-2012

(K)DK(+201.28)IGVELTGR(T)

32.55

2098-2109

(R)NLK(+201.28)HINIDQFVR(K)

31.93

1044-1055

(K)QTEATM(+15.99)TFK(+201.28)YNR(Q)

30.51

Table 3.2: List of apoB-100 peptides with lysine (represented K) residues being labeled with NHS ester
coated Fe3O4@SiO2 MNPs and detected by LC-MS/MS analysis.
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Labeled lysine residues are no longer a cleavage site for trypsin, therefore modified lysine
groups are usually located in the middle of peptide sequence and not at the C-terminus. Although
NHS ester has some reactivity toward hydroxyl group, we did not observe modification of amino
acids such as serine and tyrosine which have hydroxly group in their side chain. We were also
able to detect labeled N terminal amino acid (glutamic acid) of mature apoB-100. The MS/MS
spectra of labeled peptides were manually examined and the presence of b and y ions in the
tandom mass spectra confirmed the quality of peptide identification (Figure 3.2).

Figure 3.2:MS/MS spectrum of the labeled peptide "VNDESTEGKTSYR" of m/z 843.89 (molecular
mass of 1685.76 Da).

Our labeling protocol revealed the presence of considerably lower number of lysine
residues on the surface of intact LDL particles compare to the other approaches that utilize small
covalent modification reagents such as formaldehyde to probe surface exposed lysine groups. 13
There are 357 lysine residues present in Human ApoB-100 molecule13. NMR studies on 13Clabeled human LDL have revealed the presence of approximately 225 exposed lysine residues.
The rest of the apoB lysine groups (132 lysine residues) are buried in the lipid layer and
therefore they are not accessible to the labeling reagents.
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Although the 13C-labeling reaction was performed on intact LDL and in aqueous
medium, the modification of the surface lysine groups using the small labeling reagent ( 13Cformaldehyde) remains challenging. The long reaction time (18 hr) and very small size of the
modification reagent (compare to the size of LDL particles, 20-28 nm in diameter), increases the
chance for the labeling reagent to cross the lipid layer and modify those lysine residues which are
embedded in the hyrophobic core of LDL. Therefore, the labeling protocols that utilize small
modification reagents may overestimate the number of lysine groups exposed on surface of intact
LDL particles.
Due to the large size of our labeling reagent (NHS ester coated MNPs, 100 nm), the
covalent modification is restricted to those amine groups that are located on the surface of LDL
particles while the rest of lysine groups buried inside the LDL particles stay intact. The longer
spacer arm utilized in LC-SPDP crosslinkers improves the accessibility of further ligands to the
potential binding sites on the surface of each MNP which could result in higher conjugation
efficiency. Smaller labeling reagent (20 nm NHS ester coated Fe3O4@SiO2 MNPs) has been
also employed in our lab for the modification of surface lysine groups in proteins. In this case,
lower magnetization of small MNPs and consequently poor magnetic separation results in
significant protein loss.
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3.8 Conclusion
Thiol coated Fe3O4@SiO2 MNPs were functionalized with NHS ester groups (using
LCSPDP) to label surface lysine groups of ApoB-100 in native LDL particles. Conjugation of
LC-SPDP to thiol coated MNPs was characterized by attaching a flurophore which is reactive
towards NHS ester group. Labeling native apoB-100 by NHS ester modified Fe3O4 @SiO2 MNPs
was efficient at pH 7.4 and at room temp. Prior to MNP labeling, free thiol groups in apoB-100
were alkylated with iodoacetamide to prevent undesired disulfide bond exchange. Conjugation of
apoB-100 to MNPs facilitated SDS treatment to remove lipids and washes by various solvents to
clean the sample. Quick and efficient removal of lipids and detergent by magnetic separation can
be advantageous over conventional techniques such as dialysis, ion exchange chromatography or
precipitation. In the last step, the labeled peptides were released form MNPs by reductive
cleavage of disulfide bond in aqueous medium. MS/MS analysis of labeled peptides found 28
tryptic peptides containing labeled lysine residues. These labeled lysine residues should be on the
solvent exposed surface of LDL since the large size of MNPs prevents contact of the reagent to
those lysine residues embedded inside the structure of apoB-100. Moreover, identification of the
labeled lysine residues includes the exact positions of this amino acid residue in the full-length
sequence; and such detailed positioning of lysine residue provides additional structural
information complementary to that obtained from different methods such as NMR analysis. Due
to its ability to specifically target solvent accessible amine groups and magnetically separate
labeled peptides from detergents, NHS ester modified Fe3O4@SiO2 MNPs can be a potential tool
for sample preparation and identification of surface peptides of large and hydrophobic proteins.
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Chapter 4
Reduction of Disulfide Bonds In Peptides and Proteins Using TCEP
Immobilized Fe3O4@Sio2 Magnetic Nanoparticles

4.1 Introduction

Disulfide bonds in proteins are formed by covalent interaction between pairs of cysteine
residues. Disulfide bonds, which mostly exist in extracellular and secreted proteins,1 are formed
through the oxidative folding process in the endoplasmic reticulum.2 These covalent bonds are
essential in protein structure in many aspects including folding, assembly and stabilization of
proteins. In bacteria, the formation and reduction of disulfide bonds serves as an on-off switch,
which protects the organism against oxidative conditions.3 There are two types of disulfide bonds
in protein structures, intra- and intermolecular bonds. The former exist between two cysteine
residues within a polypeptide chain (single molecule), while the later forms between the cysteine
groups of two separate molecules of the same polypeptide or distinct proteins. Intramolecular
disulfide bonds are responsible for maintaining the tertiary structure of a protein, while the
intermolecular disulfide bonds stabilize the quaternary structure.4
The success of mass spectrometric-based analysis for identification and structural
elucidation of proteins is highly dependent on the efficiency of protein digestion steps. To ensure
efficient proteolysis, the protein should be unfolded through disulfide bond reduction and other
denaturing. The disruption of disulfide bonds enhances the accessibility of the proteolytic
enzymes to their potential cleaving sites, which consequently improves the sequence coverage
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and protein identification by mass spectrometry.5 The cleavage of disulfide bonds, which
generates free active sulfhydryl groups occurs via a reduction reaction. The reductive cleavage of
disulfide bonds in proteins is commonly carried out by simply mixing the protein solution with a
reducing agent over a specific time (ranging from 30 min to 24 hrs) at a specific temperature6
(ranging from room temperature to 60° C). The most commonly used reducing agents are thiolcontaining reductants, including dithiothreitol (DTT) and β-mercaptoethanol (BME), and
trialkylphoshines such as tris(2-carboxyethyl) phosphine (TCEP). Since DTT and BME function
via a thiol-disulfide exchange reaction, which requires the formation of a thiolate anion, the
reaction is usually inhibited at low pH7 (typically less than 8).In addition to the abovementioned
limitations, the excess amount of ME and DTT should be removed from the reaction mixture,
especially in those applications that involve the determination or modification of free thiol
groups8,9 (for example histidine tagged protein purification and maleimide conjugations). On the
other hand, trialkyl phosphines have poor water solubility and an irritant odor, which has
hindered their widespread applications as reducing agents.10
TCEP was first synthesized and used as a disulfide reducing agent by Levinson etal.11 in
1969 and Rüegg et al.12 in 1977, respectively. However, the widespread adoption of TCEP as a
disulfide bond reducing agent did not start until Burns et al. 13 established a protocol to synthesize
large quantities of TCEP. Apart from being non-volatile, non-toxic and odorless, TCEP offers
several advantages over other phosphines and thiol reducing agents, including higher resistance
to air oxidation, higher specificity and efficiency in reducing disulfide bonds and a better ability
to work over a wide range of pH (1.5-8.5). Unlike DTT and β-ME, TCEP does not have to be
removed before the chemical modification of cysteine groups in reduced protein and peptides.7

78

However, in some cases the TCEP removal is required since it can react with idodoacetic acid
and iodoacetamide compounds which are common reagents for modification of peptides and
proteins.14,15 To avoid time-consuming and laborious methods such as gel filtration or dialysis
that are common for separation of reducing agents from protein and peptides, using a solid
supported reducing agent could be an effective alternative. Immobilized TCEP disulfide reducing
agarose gel has been commercially developed which provides fast separation of reducing agent
from reduced proteins and peptides, however the application of the agarose gel- immobilized
TCEP is limited to aqueous based solutions.16 Subra et al. reported the synthesis and application
of TCEP-immobilized hydrophilic crosslinked PEG resins in conjugation with microwave
irradiation for reduction of disulfide bridges in peptides.16 Welham et al. recently reported the
fabrication and use of a TCEP-immobilized silica monolith in a glass microchip for the reduction
of disulfide bonds in insulin at 60°C17.
The immobilization of biological, organic and inorganic molecules on the surface of
magnetic nanomaterials has attracted a great deal of interest in recent decades.18Magnetic
nanoparticles offer several advantages over other types and shapes of nanomaterials due to their
unique characteristics, such as high surface area, large surface to volume ratio and
superparamagnetism, which provides the possibility of fast and easy separation of the
nanoparticle-bound ligands from the complex reaction mixture by simply using an external
magnetic field.19 In this study we have fabricated TCEP-immobilized Fe3O4 @SiO2 magnetic
nanoparticles (MNPs) for reduction of disulfide bridges in peptides and proteins. The silica shell
protects the iron oxide core from oxidation and also prevents the interaction of iron oxide with
peptides and proteins. The silica shell also provides anchoring sites for additional
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functionalization with a variety of organic groups, such as amino groups through cocondensation processes.20Due to the magnetic properties of the iron oxide core, the reducing
agent-bound nanoparticles could be isolated under mild magnetic separation conditions, which
minimizes the mechanical stress on biological samples such as proteins. The reduction reaction
was done at room temperature followed by alkylation of the generated free thiol groups to
prevent reformation of disulfide bonds. LC-ESI-MS/MS analysis was performed for qualitative
detection of alkylated cysteine groups in peptide and protein samples. The reduction of disulfide
bonds required a small amount of solid supported reducing agent and could be successfully done
in aqueous as well as organic solvents. The TCEP-immobilized silica coated magnetic
nanoparticles could be added to biological samples to maintain the reductive conditions
thatarerequired to preserve the free sulfhydryl groups against oxidation.

4.2 Experimental procedures
4.2.1 Materials
(3-Aminopropyl) triethoxysilane (APTES), iodoacetamide, ammonium bicarbonate, urea
and bovine pancreas insulin were purchased from Sigma-Aldrich (St. Louis, MO). Tris (2carboxyethyl) phosphine hydrochloride (TCEP-HCl) was purchased from Amresco (Solon, OH).
Sulfo-NHS and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC-HCl) was
purchased from ProteoChem (Loves Park, IL). Peptides containing a disulfide bridge (NGR and
Oxytocin) were purchased form Ana Spec (Fremont, CA).4-morpholineethanesulfonic
acid(MES) buffer was purchased from Pierce (Rockford, IL).Nanopure water (18.2 MΩ,
Millipore Co. Billerica, MA) was used for all experiments.
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4.2.2 Preparation of amino-functionalized Fe3O4@SiO2 magnetic nanoparticles
Supeparamagnetic nanoparticles (Fe3O4) were prepared by the hydrothermal method and
then coated with silica (Fe3O4@SiO2) using the modified stober method as described in details in
Chapter 2. To 100 mg of Fe3O4@SiO2MNP was added 80 mL of ethanol and 20 mL of water
followed by ultrasonication for 5 min. APTES (1mL) was added dropwise to the nanoparticle
suspension followed by mechanical stirring (400 rpm) for 12 hr. The amine coated
Fe3O4@SiO2MNPs were isolated using an external magnet, washed several times with water and
ethanol and finally air dried at room temperature.

4.2.3 Synthesis of TCEP coated Fe3O4@SiO2 magnetic nanoparticles
A mixture of EDC-HCl (57 mg, 0.3 mmol) and sulfo-NHS (33 mg, 0.15 mmol) in 1mL of
4-morpholineethanesulfonic acid (MES) buffer (100 mM, pH 6) was added dropwise to 500 µL
MES buffer containing 100mg (0.3 mmol ) TCEP under constant stirring over 15 min at room
temperature. The above mixture was then added to a 500 µL suspension of amine coated
Fe3O4@SiO2MNP in MES buffer followed by mechanical stirring at room temperature for 24 hr.
The TCEP coated nanoparticles were washed with 3×1 mL MES buffer, 3×1 mL water and then
dried under vacuum.
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4.2.4 Nanoparticle characterization with transmission electron microscopy (TEM) and
dynamic light scattering (DLS)
The shape and diameter of magnetic silica coated nanoparticles was identified using
transmission electron microscopy (JEOL Model 2010 LaB6 at 200 kV voltage). The modification
of nanoparticles with amine and TCEP groups was confirmed by measuring the zeta potential
values using a Mobius dynamic light scattering (DLS) instrument (Wyatt Technology
Corporation, Santa Barbara, CA). Samples were dissolved in phosphate bufferdsaline (PBS,
10mM, pH7) prior to analysis.

4.2.5 Reduction of disulfide bond in cyclic peptides using TCEP-immobilized
Fe3O4@SiO2 magnetic nanoparticles
Cyclic peptides containing a disulfide bridge (100 µg) were dissolved in 500 µL of 20%
ethanol in water. The above solution was added to 5 mg of TCEP-functionalized MNPs followed
by mechanical stirring at room temperature for 1hr. Aqueous iodoacetamide (IAA) solution (75
µL of 200 mM IAA, pH 8,50 mM ammonium bicarbonate buffer) was added to the mixture of
peptides and nanoparticles under stirring in the dark at room temperature for 30 min. The solvent
was then removed under reduced pressure and the peptides were re-suspended in 500 µL of
water. The sample was run through a C18 spin column (Pierce, Rockford, IL) to remove the salts
and then dried under vacuum. The peptides were re-suspended in 50 µL of water/
acetonitrile/formic acid (92: 5: 3, v/v) prior to LC-MS/MS analysis.
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4.2.6 Reduction of disulfide bonds in bovine pancreas insulin using TCEP-immobilized
Fe3O4@SiO2 magnetic nanoparticles
Insulin solution (20 µL of 5 µg/µL) in 50 mM hydrochloric acid was diluted to 400 µL
using 50 mM ammonium bicarbonate buffer solution (pH 8). 100 µL of 8M urea solution in
water was added to the protein solution and the mixture was stirred at 37 °C for 1 hr. The insulin
solution was treated with 5 mg of TCEP coated nanoparticles and then alkylated by IAA under
the same condition used for cyclic peptides. The MNPs were separated by an external magnet
and the reduced and alkylated protein solution was then diluted to 1mL using 50 mM ammonium
bicarbonate buffer prior to tryptic digestion. After that, the alkylated insulin sample was digested
by adding 8 µL of trypsin solution (trypsin:insulin ratio 1:30) followed by an 18 hr incubation at
37 °C. The sample was frozen using liquid nitrogen and the solvent was removed under vacuum.
The desalting step was performed as described previously followed by solvent removal under
reduced pressure. The reduced/alkylated tryptic peptides were then re-suspended in the proper
solvent before LC-MS/MS analysis.

4.2.7 LC-MS/MS and data analysis of reduced/ alkylated peptides
All Mass spectrometric analyses were performed using an Agilent 1200 HPLC system and an
Agilent 6520 Q-TOF tandem mass spectrometer (Agilent Technologies, Santa Clara, CA)
coupled with a chip cube interface. Peptide sample (2 µL) was loaded to the HPLC-Chip system
(160 nL enrichment column, 150 mm analytical column packed with C18, 5 µm beads with 300
A° pores) using a capillary pump at 4 µL/min flow rate. The peptides were then separated in the
analytical column using a nano pump at a flow rate of 600 nL/min. The MS ion source was
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operated at 300°C with nitrogen as drying gas at flow rate of 5 L/min and a fragment or voltage
of 175 V. Nitrogen was used as the collision gas and the collision energy varied as a function of
mass and charge using a slope of 3.7V/100 Da and an offset of 2.5V. The reference compounds
with the mass of 322.048121 and 1,221.990637 Da were constantly infused into the ion source
during the analysis. All analyses were performed in positive ion mode. LC chromatogram and
mass spectra were analyzed using Mass-Hunter (Version B.0301; Agilent Technologies) and
PEAKS (Bioinformatics Solutions Inc,Ontario1, Canada) software.

4.3 Result and discussion
4.3.1 Surface modification of Fe3O4@SiO2 nanoparticles with TCEP
The magnetite core and the Fe3O4@SiO2 nanoparticles were prepared following the same
methods that have been described in Chapter 2. The Fe3O4@SiO2 nanoparticles were spherical
with the average diameter of 100 nm. The surface of silica coated nanoparticles was
functionalized by amino groups via co-condensation reaction of silanol groups of the silica shell
and APTES (Figure 4.1a). The APTES coating did not change the shape and size of the
nanoparticles as confirmed by TEM (data not shown). The successful functionalization of silica
coated nanoparticles with amino groups was investigated by measuring the zeta potential values
of nanoparticle solutions in 10mM PBS buffer (pH 7) using DLS. The zeta potential for
Fe3O4@SiO2 and amine coated Fe3O4@SiO2 were found to be -23±5 mV and +28±2 mV,
respectively. The negative zeta potential value for silica coated iron oxide nanoparticles is
associated with deprotonation of silanol groups at pH 721. On the other hand, the positive zeta
potential value for the amine coatedFe3O4@SiO2MNPswas due to amine groups which were
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protonated at neutral pH22. The large change in zeta potential confirms modification of the
particles with APTES.

(a)

(b)

Figure 4.1: (a) Synthesis of TCEP-immobilized Fe3O4@SiO2MNPs and (b) reduction of disulfide bonds
in proteins and peptides using TCEP functionalized magnetic nanoparticles.

The amino groups on the surface of Fe3O4 @SiO2 nanoparticles were then utilized for
immobilization of TCEP groups on the nanoparticles surface via an amide bond formation
between the surface amine groups and the carboxylic acid group of TCEP. The coupling reaction
was accomplished by activation of one carboxylic acid group of TCEP with one equivalent of
EDC coupling reagent in the presence of sulfo-NHS (Figure 4.1a). The Sulfo-NHS was used
along with EDC to improve the efficiency of the coupling reaction by generating a more stable
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amine reactive intermediate.23 Due to higher reactivity of EDC in acidic condition,24 the coupling
reaction was performed in MES buffer solution (100 mM, pH 6). To minimize the chance of
nanoparticle cross-linking, the EDC and sulfo NHS mixtures was added dropwise to the TCEP
solution. The activated TCEP was then coupled to the amine groups on the surface of
nanoparticles. The TCEP coated nanoparticles were then washed multiple times with MES buffer
solution and water to remove byproducts and unreacted materials. The zeta potential of the
TCEP coated nanoparticles in PBS buffer (10 mM, pH 7) was found to be -33±5 mV. The
negative zeta potential, which was due to the deprotonation of TCEP carboxylic acid groups,
indicated the replacement of amine groups with TCEP groups on the surface of the nanoparticles.

4.3.2 Reduction and alkylation of cyclic peptides
To evaluate the ability of TCEP-immobilized Fe3O4@SiO2 MNPsto cleave disulfide
bonds, two cyclic peptides, NGR and oxytocin (Table 4.1), were selected as models for disulfide
bond reduction. Each peptide had two cysteine groups linked by a disulfide bond. Table 4.1
shows the sequence as well as m/z values for singly protonated ions of cyclic NGR and oxytocin
peptides employed in this study. No evidence of in-source disulfide bond cleavage was observed
in the ESI-MS/MS spectrum of each cyclic peptide, which is expected under low energy CID
conditions.25
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Cyclic
peptides

Peptide sequence

MW

( M+ H+)

calculated

m/z found

NGR

H-Cys-Asn-Gly-Arg-Cys-Gly-Gly-Leu-Val-Thr-Thr-OH

1078.3

1079.9

Oxytocin

H-Gly-Leu-Pro-Cys-Asn-Gln-Ile-Tyr-Cys-OH

1008.2

1007.7

Table 4.1: Sequences of cyclic peptides used in this study. Each peptide contains two cysteine residues
connected by an intramolecular disulfide bond.

Reduction of the cyclic peptides was performed in 20% ethanol/water mixture, with a
final peptide concentration of 0.2 mg/mL. TCEP immobilized nanoparticles were added to the
peptide solution and the reaction was carried out at room temperature. During the incubation of
the peptide solution with TCEP coated nanoparticles, the disulfide bonds in the peptides reacted
with the reducing agent, resulting in cleavage of the disulfide bond and the oxidation of TCEP to
the phosphine oxide (Scheme 4.1b). After the reduction reaction, The MNPs were seperated and
the reduced peptides were immediately treated with iodoacetamide to protect the reactive
sulfuhydryl groups from oxidation and reformation of disulfide bond via carbamidomethylation
reaction. The sample was then desalted using a C18 spin column (Pierce, Rockford, IL) and
dried. The reduced and alkylated peptides were re-suspended in a mixture of
water/acetonitrile/formic acid (92: 5: 3, v/v) and analyzed with LC/MS/MS using an Agilent
1200 LC system, an Agilent Chip Cube interface, and an Agilent 6520 Q-TOF tandem mass
spectrometer (Agilent Technologies, Santa Clara, CA).The disulfide bond reduction followed by
the addition of carbamidomethyl group to the thiol moieties resulted in a mass increase of 57.07
Da for each modified cysteine in NGR and oxytocin peptides. The LC/MS spectra of reduced
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and alkylated oxytocin and NGR showed the presence of the peptides with two cysteine groups
being alkylated with IAA. In the ESI/MS spectrum of the reduced/alkylated NGR (Figure 4.2a),
the singly charged ion at m/z 1193.94 and the doubly charged ion at m/z 597.47 correspond to
NGR with both cysteine residues being modified by carbamidomethyl groups. In the case of
oxytocin (Figure 4.3a), the alkylation of two cysteine residues was confirmed by the appearance
of singly and doubly charged ions atm/z 1121.74 and 561.37, respectively. The collision induced
dissociation (CID) of alkylated, doubly charged NGR and oxytocin precursor ions at m/z 597.47
and 561.37 generated a series of fragment ions (Figures 4.2b and 4.3b) which were matched with
the theoretically calculated b and y ions. The presence of b and y ions in the MS/MS spectrum,
confirmed the successful reduction/alkylation of the disulfide bond in both peptides.
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Figure 4.2: ESI analysis of NGR peptide before (a) and after (b) reduction reaction using TCEP-coated
MNPs. a) In this mass spectrum, the peaks at m/z 1079.47 and 540.23 correspond to singly and doubly
charged ions , respectively. c) The singly charged ion at m/z 1193.51 and doubly charged ion at m/z
597.26 correspond to reduced NGR with both cysteine residues modified with carbamidomethyl group. b)
MS/MS spectra of the doubly charged reduced/alkylated NGR.
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Figure 4.3: ESI analysis of oxytocin peptide before (a) and after (b) reduction reaction using TCEP-coated
MNPs. a). In this mass spectrum, the peaks at m/z 1007.7 and 504.85 correspond to singly and doubly
charged ions, respectively. c) The singly charged ion at m/z 1121.48 and the doubly charged ion at m/z
561.25 correspond to reduced NGR with both cysteine residues modified with carbamidomethyl group. b)
MS/MS spectra of the doubly charged reduced/alkylated oxytocin.
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4.3.3 Reduction and alkylation of bovine pancreas insulin
To assess the ability of TCEP-immobilized Fe3O4@SiO2MNPs to reduce disulfide bonds
in proteins, bovine pancreas insulin was selected as the target protein. To prepare the sample
solution, insulin (100 µg in 400 µL ammonium bicarbonate buffer, pH 8) was first denatured by
reacting with urea (100 µL of 8 M urea solution) at 37°C for 1 hr. The reduction of insulin
disulfide bonds using TCEP coated nanoparticles was performed in a similar way as with the
cyclic peptides. The reduced protein was then alkylated using IAA as described in the previous
section to prevent the reformation of disulfide bonds. The magnetic nanoparticles were separated
and the reduced/alkylated protein was further subjected to trypic digestion. The tryptic peptides
were run through C18 spin column (Pierce, Rockford, IL) and the solvent was removed under
vacuum. The acquired LC-MS/MS raw data were processed by PEAKS (Bioinformatics
Solutions Inc,Ontario1, Canada) and the search parameters employed for database search were as
follows: differential mass increase of 57.07 Da for carbamidomethylated cysteine residues, and
15.99 Da for oxidation of methionine residues. Bovine insulin consists of 51 amino acids in two
polypeptide chains, the amino terminal B chain containing 30 amino acids and the caboxylterminal A chain with 21 amino acids. Insulin contains six cysteine residues which form two
interchain disulfide bonds and one intrachain bond within the A polypeptide. The results of the
ESI-MS/MS analysis of reduced/alkylated bovine insulin are summarized in Table 4.2. The
successful cleavage and alkylation of two insulin interchain disulfide bonds (A7-B7 and B19A20) was proved by carbamidomethylation of the A7, B7, B19 and A20 residues. The alkylation
of A6 and A11 residues (Table 4.2) also confirmed the reduction/alkylation of the intrachain
(A6-A11) disulfide bond. Figure 4.4 shows the MS/MS spectrum of a reduced/alkylated peptide
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in theA chain of insulin (A8-A21, table 1). The sequence of the peptide was confirmed by
matching the b and y ions with the detected m/z values.

Reduced/alkylated
Peptide sequence

- log p

A8- A21

(C)ASVC(+57.02)SLYQLENYC(+57.02)N

106.94

B6- B22

(H)LC(+57.02)GSHLVEALYLVC(+57.02)GER(G)

87.19

A3-A13

(I)VEQC(+57.02)C(+57.02)ASVC(+57.02)SL(Y)

71.85

A9- A21

(A)SVC(+57.02)SLYQLENYC(+57.02)N

62.19

B10-B22

(S)HLVEALYLVC(+57.02)GER

56.95

A7- A21

C(+57.02)ASVC(+57.02)SLYQLENYC(+57.02)N

45.64

peptides

Table 4.2:.List of peptides in A and B chains of bovine insulin obtained by LC-MS/MS analysis of
reduced/alkylated bovine insulin. All cysteine residues in A and B chains of insulin were modified with
carbamidomethylgroup.
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Figure 4.4:MS/MS spectrum of the reduced/alkylated peptide "ASVCSLYQLENYCN" of m/z 860.85
(molecular mass of 1719.72 Da)

4.4 Conclusion
TCEP coated MNPs have been fabricated as novel solid supported reducing agents to
cleave disulfide linkages in peptides and proteins. Amine groups on the surface of
Fe3O4@SiO2MNPs were covalently conjugated to carboxylic acid groups of TCEP via EDC
coupling reaction. The surface functionalization of nanoparticles with amine and TCEP groups
was confirmed by zeta potential measurements using DLS. The reduction reaction by TCEP
immobilized MNPs was performed in water for protein samples and water /ethanol mixtures for
peptides samples.
The results from LC-MS/MS analysis of cyclic peptides and protein samples treated with
TCEP coated Fe3O4@SiO2 MNPs, clearly indicated the ability of our reducing agent
immobilized MNPs to efficiently cleave disulfide bonds in both organic and aqueous solvents at
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room temperature. The TCEP-immobilized magnetic nanoparticles can be easily separated from
the reaction mixture using an external magnet, which eliminates the need to use time-consuming
separation methods such as gel filtration and dialysis. This minimizes the sample loss and
enhances the sensitivity of sample analysis. Easy and fast reduction procedure, mild reaction
condition, less sample processing step, and easy separation makes TCEP-immobilized MNPs an
efficient tool for reduction of portions. Future studies include the determination of TCEP loading
capacity of the MNPs as well as the reusability of our TCEP-coated MNPs for reduction of
disulfide bonds.

94

References
1. Stark GR., Stern. K., Atala. A., Yoo J., Methods Enzymol, 1977, 47 (2): 129–32.
2. Chakravarthi S., Jessop C. E.,Bulleid N. J., EMBO Reports, 2006, 7(3), 271–275.
3. Cabiscol E., Tamarit J., Ros J., Int Microbiol, 2000 Mar;3(1):3-8.
4. Nakamoto H., Bardwell J.C., Biochim Biophys Acta, 2004, Nov 11;1694(1-3):111-9.
5. M. Scigelova P., Green A., Giannakopulos A., Rodger D. Crout, and P. Derrick, Eur. J.
Mass Spectrom., 2001, 7, 29–34.
6. N. J. Hauser and F. Basile, J. Proteome Res., 2008, 7, 1012–1026.
7. Getz E.B., Xiao M., Chakrabarty T., Cooke R., Selvin P.R., Anal Biochem, 1999,
273(1):73-80.
8. Visser C. C., Heleen Voorwinden, J. Drug Targeting, 2004, 12, 569−573.
9. Schumacher F. F., Nobles M., Ryan Bioconjugate Chem., 2011, 22, 132−136.
10. P. D. Tzanavaras, C. Mitani, A. Anthemidis and D. G. Themelis, Talanta, 2012, 96, 21–
25.
11. M. E. Levison, A. S. Josephson, D. M. Kirschenbaum, Experientia 1969, 25, 126-127.
12. U. T. Rüegg, J. Rudinger, Academic Press, San Diego, 1977.
13. J. A. Burns, J. C. Butler, J. Moran, G. M. Whitesides, J. Org. Chem, 1991, 56, 26482650.
14. Shriver-Lake L.C., North S.H., Rowe Taitt C., Biotechniques, 2013, 55(6):292-4
15. Shafer D.E., J.K. Inman, and A. Lees, 2000, Biochem, 282:161-164.
16. G. Miralles, P. Verdi´e, G. Subra, ACS Comb. Sci., 2013, 15, 169–173.

95

17. Alzahrani E. and K. Welham, Analytical Methods, 2014, 6(2): p. 558-568.
18. Wu. W., He Q., and Jiang C., 2008, Nanoscale Research Letters, 3(11), 397–415.
19. Laurent S., Forge D., Port M., Roch A., Robic C., Vander Elst. L., and Muller R. N.,
2008, Chem. Rev., 108 (6), 2064−2110.
20. M. Etienne and A. Walcarius, Talanta, 2003, 59, 1173–1188.
21. Hakami O., Zhang Y., Banks C.J., Water Res., 2012, 46(12):3913-22
22. Schiestel T., Brunner H., Tovar G.E., J. Nanosci Nanotechnol, 2004 May;4(5):504-11.
23. S. Ravindran, S. Chaudhary, B. Colburn, M. Ozkan and C. S. Ozkan, Nano Lett., 2003, 3,
447–453.
24. N. O. Dhoot, C. A. Tobias, I. Fischer and M. A. Wheatley, J. Biomed. Mater. Res., Part
A, 2004, 71, 191–200.
25. Lioe H., O. Hair R.A., J. Am. Soc. Mass Spectrom., 2007 Jun;18(6):1109-23.

96

Chapter 5
Conclusions
Qualitative and quantitative characterization of NHS ester groups immobilized on the
surface of Fe3O4@SiO2 MNPs was performed by fluorescence based methods. The presence of
NHS ester groups on the surface of nanoparticles was confirmed by green fluorescence of
dansylcadaverine fluorophore conjugated to MNPs using fluorescence microscopy. The accurate
quantification of NHS ester groups was carried out by reductive cleavage of disulfide bond in the
linker between the fluorophore and MNPs followed by fluorometric detection of the released
fluorophore. The labeling efficiency of native protein with NHS ester functionalized MNPs was
also investigated. Maintaining the concentration of fresh NHS ester coated MNPs during the
conjugation reaction plays a critical role in maximizing the number of MNPs conjugated per
protein molecule or maximizing the number of proteins being labeled in a complex mixture such
as cell surface proteome. The methods presented in this study provide better estimation of active
functional groups on the surface of nanoparticles that are available for further conjugation with
chemical or biomolecules.
NHS ester modified Fe3O4 @SiO2 MNPs were utilized to label amine groups in surface
exposed segments of apoB-100 in intact human LDL under physiological condition (aqueous
medium, ambient temperature, neutral pH). Easy, efficient and quick delipidation of apoB-100
was achieved using SDS treatment and magnetic separation. Magnetic separation also provided
fast and efficient removal of the detergent which is essential for maintaining the activity of
proteolytic enzymes and preventing signal suppression in LC-MS/MS analysis. The apoB-100
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tryptic peptides were released from MNPs by cleaving the disulfide bond linker under mild
condition (aqueous solution, ambient temperature).
The labeled lysine residues (with distinct mass shift) and their position in the full length
of apoB-100 sequence were identified by LC-MS/MS. The MS/MS analysis revealed 30 labeled
peptides which are believed to present on the surface of intact LDL particles since the lysine
residues embedded inside the lipid core of LDL are not reachable by our bulky labeling reagent.
High efficiency and specificity of NHS ester reaction with amine groups makes our labeling
reagent a useful tool to identify surface exposed segments of large hydrophobic proteins. Results
from in vitro studies provided us some useful structural information about apoB-100. LDL
oxidation causes structural changes in protein. Therefore, we would like to map apoB-100 on the
surface of LDL samples acquired from patients with different clinical stages of atheroschelerosis
using NHS ester functionalized nanoparticles and compare the results with our in vitro studies.
Reduction and alkylation of cyclic peptides and proteins was performed successfully
using TCEP- immobilized Fe3O4 @SiO2MNPs. The surface of silica coated MNPs was first
functionalized with amine groups followed by TCEP immobilization in presence of EDC and
sulfo-NHS. DLS studies confirmed amine and TCEP surface fictionalization of MNPs. The
reduction and alkylation of disulfide linkages in peptides and proteins using TCEP-Coated MNPs
was achieved in one step at room temperature in both organic and aqueous solvents that was
confirmed by LC-MS/MS analysis. The reducing agent was easily separated from protein
solution by magnetic separation. Compare to the conventional methods, utilizing TCEPimmobilized MNPs provides the chance to perform fast and one step reduction/ alkylation of
proteins and peptides at room temperature with minimal sample loss. Future work involves
accurate quantification of TCEP groups on the surface of MNPs. We would also like to evaluate
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the reusability of the reducing agent immobilized MNPs as well as their ability to reduce
disulfide bonds in complex proteins such as apoB-100.
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